

## AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (May 2004) are preceded by S1.

### *Notice to Readers*

Please be advised that the numbering of online-only items in the print tables of contents of the January through June 2004 issues of **AJKD** and in this index is inconsistent with the numbering of those items online. Please refer to [www.ajkd.org](http://www.ajkd.org) for the appropriate numbering of online-only items, which is how these items are cited in *Index Medicus/MEDLINE/PubMed*. We regret the inconvenience.

- |                            |                         |                               |
|----------------------------|-------------------------|-------------------------------|
| Aasarød, K., 485           | Baba, M., 1:E1          | Bodaghi, B., 209              |
| Abbas, A., 1:E2            | Bader, R., 28           | Bodingbauer, M., 1065         |
| Abbott, K.C., 120          | Baelde, H.J., 636       | Boer, T.S., 330               |
| Acott, P.D., 296           | Bahr, M.J., 342         | Boeschoten, E.W., 891         |
| Adamson, J.W., 464         | Baigent, C., 244        | Bone Turnover Work Group, 558 |
| Adler, L., 600             | Baik, G.-H., 1109       | Bonsib, S.M., 1138            |
| Afzali, B., 234            | Ball, S., 244           | Bookman, I., 2:E8             |
| Agarwal, G., 3:E10         | Ballardie, F.W., 3:E15  | Border, W.L., 721             |
| Agodoa, L.Y.C., 120        | Balogun, R.A., 365      | Bouloukos, V.I., 589          |
| Aguera, M., 685            | Balow, J.E., 383        | Bowden, D.W., 796             |
| Ahmed, S.I., 424           | Banas, B., 286          | Braun, N., 10                 |
| Ala-Houhala, I., 809       | Banba, M., 918          | Brown, A., 836                |
| Albrechtsen, G.E., 485     | Banerjee, A., 103       | Brown, E., 103                |
| Alisir, S., 854            | Banfi, G., 28           | Bruijn, J.A., 368, 636        |
| Aljama, P., 685            | Barker, J., 1008        | Budde, K., 923                |
| Allon, M., 1008            | Bartlett, L.H., 61      | Bukovsky, R., 67              |
| Alonso, A., 1              | Batuman, V., 629        | Burns, A., 651                |
| Alric, L., 617             | Baumann, G., 444        | Burright, R.G., 705           |
| Amann, K., 572             | Bay, W.H., 3:E10        |                               |
| Amann, R., 846             | Bazzano, L.A., 629      | Cacoub, P., 617               |
| Ames, R., 3:xlvi           | Beck, S.R., 796         | Cai, W., 690                  |
| Andreoni, K.A., 1082       | Belani, S.S., 320       | Cannata-Andia, J., 566        |
| Andreucci, V.E., 782       | Bellanuova, I., 479     | Caridi, G., 727               |
| Angstwurm, M.W.A., 4:E16   | Bellizzi, V., 782       | Castaneda, C., 607            |
| Anjum, S., 1071            | Bellomo, R., 444        | Cataliotti, A., 479           |
| Ansari, N., 424            | Benedetto, F.A., 479    | Cavenagh, J., 2:E4            |
| Arakawa, Y., 5:E20         | Benoit, D., 817         | Chadban, S.J., 197            |
| Arif, F., 3:xlvi           | Berdeli, A., 727        | Chak, W.L., 910               |
| Arimura, Y., 4:E17         | Bergstein, J., 1138     | Chan, A.K.Y., 801             |
| Arlt, V.M., 4:E18          | Bergstralh, E.J., 112   | Chan, J.Y.S., 801             |
| Arnett, D.K., 836          | Berland, Y., 3:E14      | Chan, W.W.M., 801             |
| Ashby, V.B., 1014          | Bernstein, P., 663      | Chan, Y.H., 910               |
| Astor, B.C., 836           | Berry, J.L., 3:E15      | Chandrasekar, T., 531         |
| Athyros, V.G., 589         | Billensteiner, E., 1065 | Chang, C.-J., 74              |
| Atkins, R.C., 85, 197, 696 | Bishop, C.W., 877       | Chang, S.-T., 1040            |
| Attia, A.-M., 424          | Bitzan, M., 976         | Chao, Y.-W., 2:E6             |
| Au, T.C., 269              | Blagg, C.R., 90, 939    | Chapuis, O., 161              |
| Aucouturier, P., 1:E2      | Blanco, P., 846         | Charney, D., 3:xlvi           |
| Austin III, H.A., 383      | Blann, A.D., 244        | Chatelut, E., 140             |
| Ayanian, J.Z., 350         | Bley, T.A., 358         | Chau, K.F., 910               |
| Ayus, J.C., 999            | Block, G.A., 572        | Chebrolu, S.B., 90            |
|                            | Bloom, E., 2:E9         | Chen, C.-C., 1040             |

## AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (May 2004) are preceded by S1.

### *Notice to Readers*

Please be advised that the numbering of online-only items in the print tables of contents of the January through June 2004 issues of **AJKD** and in this index is inconsistent with the numbering of those items online. Please refer to [www.ajkd.org](http://www.ajkd.org) for the appropriate numbering of online-only items, which is how these items are cited in *Index Medicus/MEDLINE/PubMed*. We regret the inconvenience.

- |                            |                         |                               |
|----------------------------|-------------------------|-------------------------------|
| Aasarød, K., 485           | Baba, M., 1:E1          | Bodaghi, B., 209              |
| Abbas, A., 1:E2            | Bader, R., 28           | Bodingbauer, M., 1065         |
| Abbott, K.C., 120          | Baelde, H.J., 636       | Boer, T.S., 330               |
| Acott, P.D., 296           | Bahr, M.J., 342         | Boeschoten, E.W., 891         |
| Adamson, J.W., 464         | Baigent, C., 244        | Bone Turnover Work Group, 558 |
| Adler, L., 600             | Baik, G.-H., 1109       | Bonsib, S.M., 1138            |
| Afzali, B., 234            | Ball, S., 244           | Bookman, I., 2:E8             |
| Agarwal, G., 3:E10         | Ballardie, F.W., 3:E15  | Border, W.L., 721             |
| Agodoa, L.Y.C., 120        | Balogun, R.A., 365      | Bouloukos, V.I., 589          |
| Aguera, M., 685            | Balow, J.E., 383        | Bowden, D.W., 796             |
| Ahmed, S.I., 424           | Banas, B., 286          | Braun, N., 10                 |
| Ala-Houhala, I., 809       | Banba, M., 918          | Brown, A., 836                |
| Albrechtsen, G.E., 485     | Banerjee, A., 103       | Brown, E., 103                |
| Alisir, S., 854            | Banfi, G., 28           | Bruijn, J.A., 368, 636        |
| Aljama, P., 685            | Barker, J., 1008        | Budde, K., 923                |
| Allon, M., 1008            | Bartlett, L.H., 61      | Bukovsky, R., 67              |
| Alonso, A., 1              | Batuman, V., 629        | Burns, A., 651                |
| Alric, L., 617             | Baumann, G., 444        | Burright, R.G., 705           |
| Amann, K., 572             | Bay, W.H., 3:E10        |                               |
| Amann, R., 846             | Bazzano, L.A., 629      | Cacoub, P., 617               |
| Ames, R., 3:xlvi           | Beck, S.R., 796         | Cai, W., 690                  |
| Andreoni, K.A., 1082       | Belani, S.S., 320       | Cannata-Andia, J., 566        |
| Andreucci, V.E., 782       | Bellanuova, I., 479     | Caridi, G., 727               |
| Angstwurm, M.W.A., 4:E16   | Bellizzi, V., 782       | Castaneda, C., 607            |
| Anjum, S., 1071            | Bellomo, R., 444        | Cataliotti, A., 479           |
| Ansari, N., 424            | Benedetto, F.A., 479    | Cavenagh, J., 2:E4            |
| Arakawa, Y., 5:E20         | Benoit, D., 817         | Chadban, S.J., 197            |
| Arif, F., 3:xlvi           | Berdeli, A., 727        | Chak, W.L., 910               |
| Arimura, Y., 4:E17         | Bergstein, J., 1138     | Chan, A.K.Y., 801             |
| Arlt, V.M., 4:E18          | Bergstralh, E.J., 112   | Chan, J.Y.S., 801             |
| Arnett, D.K., 836          | Berland, Y., 3:E14      | Chan, W.W.M., 801             |
| Ashby, V.B., 1014          | Bernstein, P., 663      | Chan, Y.H., 910               |
| Astor, B.C., 836           | Berry, J.L., 3:E15      | Chandrasekar, T., 531         |
| Athyros, V.G., 589         | Billensteiner, E., 1065 | Chang, C.-J., 74              |
| Atkins, R.C., 85, 197, 696 | Bishop, C.W., 877       | Chang, S.-T., 1040            |
| Attia, A.-M., 424          | Bitzan, M., 976         | Chao, Y.-W., 2:E6             |
| Au, T.C., 269              | Blagg, C.R., 90, 939    | Chapuis, O., 161              |
| Aucouturier, P., 1:E2      | Blanco, P., 846         | Charney, D., 3:xlvi           |
| Austin III, H.A., 383      | Blann, A.D., 244        | Chatelut, E., 140             |
| Ayanian, J.Z., 350         | Bley, T.A., 358         | Chau, K.F., 910               |
| Ayus, J.C., 999            | Block, G.A., 572        | Chebrolu, S.B., 90            |
|                            | Bloom, E., 2:E9         | Chen, C.-C., 1040             |

- Chen, C.-F., 74  
 Chen, C.-H., 1091  
 Cheng, C.-H., 1091  
 Cheng, N.-L., 304  
 Cheng, Y.L., 910  
 Chertow, G.M., 868  
 Chiang, H.-W., 1047  
 Chiche, L., 3:E14  
 Chimienti, S., 471  
 Choi, K.S., 910  
 Choi, P., 103  
 Chow, T.C., 580  
 Christen, E., 976  
 Chu, C.-M., 1040  
 Cianciaruso, B., 782  
 Ciccone, J.S., 1104  
 Ciechanowicz, A., 983  
 Cleary, P.D., 350  
 Cnaan, A., 976  
 Coburn, J.W., 558, 877  
 Coco, M., 566  
 Coen, G.M., 558  
 Cohen, E., 2:E3  
 Cohen, L., 172  
 Cohen-Solal, M., 566  
 Colardyn, F., 817  
 Collins, A.J., 464  
 Collins, J., 492  
 Constantinescu, A.R., 976  
 Conte, G., 782  
 Cook, T., 4:E18  
 Cooper, B.A., 61  
 Cooper, M.E., 1113  
 Coresh, J., 836  
 Coritsidis, G.N., 424  
 Cosio, F.G., 112  
 Coyne, D.W., 320  
 Craig, J.C., 752  
 Cristofano, C., 471  
 Crocker, J.F.S., 296  
 Cruess, D.F., 120  
 Cunningham, J., 313, 566  
 Cura, A., 727  
 Czekalski, S., 983  
  
 D'Agati, V.D., 186, 368, 388  
 Dagnino, M., 727  
 Dahl, D.C., 1071  
 Daily Hemodialysis Study Group, 90  
 D'Ambrosio, C., 900  
 Daniel, L., 3:E14  
 Daniels, S.R., 721  
 Danielson, B., 1071  
 Dart, R.A., 172  
 Davenport, A., 2:xliv  
 David-Kasdan, J.A., 350  
 Davies, M., 3:E15  
 Davis, C.L., 508, 1116  
 Davison, S.N., 172  
 de Heer, E., 636  
 de Jong, P.E., 330, 966  
  
 Dekker, F.W., 891  
 Delano, B., 90  
 Demirel, S., 854  
 De Nicola, L., 782  
 Deray, G., 209  
 Desnick, R.J., 164, 186  
 DeVita, M.V., 3:E12  
 Dhondt, A., 817  
 Di Duca, M., 727  
 Dingemans, J., 923  
 Disdier, P., 3:E14  
 Diza-Mataftsi, E., 544  
 Donckerwolcke, R., 399  
 Donovan, P.J., 705  
 Doran, P.P., 636  
 Drüeke, T.B., 552  
 Durham, J.H.C., 186  
 Dursun, M., 854  
 Dussol, B., 3:E14  
 Dworacki, G., 983  
  
 Eder, T., 854  
 Economidou, D., 544  
 Edelstein, C.L., 405  
 Efrati, E., 600  
 Efstratiadis, G., 544  
 Eguchi, J., 1:E1  
 Eikmans, M., 636  
 Elangovan, L., 877  
 Elhabashi, A.F., 131  
 El-Husseini, A.A., 131  
 Elisaf, M., 223, 589  
 Elsayy, E., 131  
 Embert, C.D., 1104  
 Epstein, A.M., 350  
 Erbay, B., 6:E25  
 Erdogan, D., 854  
 Ergün, I., 6:E25  
 Ernst, T., 342  
 Ertürk, S., 6:E25  
 Espinosa, M., 685  
  
 Fang, J.-T., 1040  
 Farooq, V., 531  
 Fathi, R., 45  
 Faubel, S., 405  
 Feigin, A., 663  
 Felten, H., 358  
 Ferris, M.E., 1082  
 Fervenza, F.C., 147  
 Fiebeler, A., 286  
 Filler, G., 624  
 Fink, N.E., 900  
 Finney, H., 502  
 Fischer, M.J., 415  
 Fitzpatrick, L., 566  
 Flanc, R.S., 197  
 Fliser, D., 342  
 Föding, M., 1098  
 Fogo, A.B., 4:xliv, 368, 933  
 Foroozan, R., 5:E23  
  
 Freedman, B.I., 796  
 Fried, L.F., 861  
 Fried, L.P., 861  
 Fuiano, G., 782  
 Fujigaki, Y., 53  
 Fukagawa, M., 558  
 Fukasawa, H., 53  
 Fünfstück, R., 10  
 Fung, J.W.H., 801  
 Furberg, C.D., 37  
 Fushimi, T., 5:E22  
 Futami, K., 5:E20  
  
 Gal, A., 538  
 Gandhi, V.C., 90  
 Gans, R.O.B., 966  
 Garces, J., 2:E9  
 García de Vinuesa, S., 846  
 Garty, M., 2:E3  
 Geddes, C.C., 763  
 Germain, M.J., 172, 877  
 Gertz, M.A., 147  
 Giggeri, G.M., 727  
 Ghijsels, E., 5:E24  
 Giachelli, C., 572  
 Giaccone, G., 479  
 Gilbertson, D.T., 464  
 Ginsburg, E., 772  
 Gipson, D.S., 1082  
 Glascock, B.J., 721  
 Goicoechea, M., 846  
 Goldberg, A.C., 320  
 Goldsmith, D., 313  
 Goldsmith, D.J.A., 234  
 Goltzmann, D., 566  
 Gómez-Campderá, F., 846  
 Good, K.S., 933  
 Goodman, W.G., 572  
 Gordon, P.L., 607  
 Grabensee, B., 10  
 Granata, A., 1:xliv  
 Granel, B., 3:E14  
 Gröne, H., 538  
 Gupta, M., 67  
 Gussak, H.M., 112  
 Gutierrez, M.J., 846  
  
 Haas, M., 1065  
 Hafer, C., 342  
 Hagiwara, M., 433  
 Hallan, S., 485  
 Haller, H., 286, 342  
 Halperin, M.L., 304  
 Haluska, B., 45  
 Hama, Y., 1030  
 Hara, S., 733  
 Hartog, J.W.L., 966  
 Hasegawa, O., 918  
 Hasuike, Y., 1030  
 Hataya, H., 918  
 He, J., 629

- Hebert, J.R., 415  
 Hebert, L.A., 3:E10, 757  
 Heering, P., 10  
 Hegarty, J., 531  
 Heidbreder, E., 538  
 Held, P.J., 1014  
 Hernández, D., 999  
 Hernandez, R.A. Jr., 3:E10  
 Herzenberg, A.M., 2:E8  
 Hibi, I., 454  
 Higuchi, A., 3:E11  
 Higuchi, K.-i., 5:E22  
 Hildebrandt, F., 358  
 Hirayama, K., 433  
 Hirota, Y.-i., 5:E20  
 Hishida, A., 53  
 Hlatky, M.A., 868  
 Hoehner, B., 923  
 Hoefele, J., 358  
 Holley, J.L., 172  
 Hollstein, M., 4:E18  
 Honda, M., 918  
 Hong, H.K., 19  
 Hörnl, W.H., 1065, 1098  
 Hoshii, Y., 5:E22  
 Hoshino, J., 733  
 Hoste, E., 817  
 Houghton, J.B., 531  
 Hoy, W.E., 254  
 Hricik, D.E., 1116  
 Hruska, K.A., 572  
 Hsia, C.-C., 2:E7  
 Hsieh, I.-C., 1040  
 Hsu, L.-A., 74  
 Hsu, Y.-H., 2:E7  
 Hsu, Y.-J., 304  
 Hsu, T.-S., 74  
 Huang, C.-C., 74  
 Huang, H.-L., 1040  
 Huang, J.-W., 1047  
 Huang, K., 1082  
 Huisman, R.M., 330  
 Hujairi, N.M.A., 234  
 Hulbert-Shearon, T.E., 1014  
 Hulley, S.B., 868  
 Humen, D.P., 5:E21  
 Hung, K.-C., 1040  
 Hung, K.-Y., 1047  
 Hurme, M., 809  
  
 Iaina, N.L., 2:E3  
 Ichimura, K., 1:E1  
 Ikeda, M., 918  
 Ikeda, S.-i., 5:E22  
 Ikegaya, N., 454  
 Imbriano, L., 186  
 Ing, T.S., 90  
 Ireland, C., 868  
 Isbel, N., 45  
 Ishida, Y.-i., 5:E20  
 Ishikawa, N., 1024  
 Ishikura, K., 918  
 Ivens, K., 10  
  
 Iwasaka, T., 3:E13  
 Iwata, Y., 5:E20  
 Izopet, J., 140  
 Izuhara, Y., 1024  
 Izumi, M., 1030  
 Izzedine, H., 209  
  
 Jaber, B.L., 1  
 Jager, K.J., 891  
 Jain, S.K., 154  
 Jancovici, R., 161  
 Jani, A., 405  
 Jarmulowicz, M., 651  
 Jassal, S.V., 2:E8  
 Jogo-Desplat, S., 3:E14  
 Jennette, J.C., 368  
 Jindal, R.M., 943  
 John, R., 825  
 Johnson, D., 45  
 Johnson, D.W., 492  
 Johnson, R.J., 739  
 Johnston, M., 651  
 Jones, G., 2:xlili  
 Junsanto, T., 164  
  
 Kabir, A., 757  
 Kaizu, Y., 454  
 Kakuta, T., 1024  
 Kalantar-Zadeh, K., 671  
 Kalra, P.A., 531  
 Kamar, N., 140  
 Kametani, F., 5:E22  
 Kanakiriya, S., 147  
 Kandaswamy, C., 1071  
 Kanegane, H., 3:E11  
 Kanno, Y., 1056  
 Kantarci, G., 817  
 Kaplan, B.S., 976  
 Kasiske, B.L., 1071  
 Katori, H., 733  
 Kavanagh, D., 763  
 Kawai, K., 5:E20  
 Keller, F., 10  
 Keogh, J.H., 350  
 Kerjaschki, D., 933  
 Kerr, P.G., 85, 197, 696  
 Ketteler, M., 572  
 Keven, K., 6:E25  
 Khamash, H., 424  
 Khosla, U.M., 739  
 Khoury, P.R., 721  
 Kielstein, J.T., 342  
 Kijima, Y., 3:E13  
 Kim, D.-J., 1109  
 Kim, H.-K., 1109  
 Kim, J.-B., 1109  
 Kim, J.H., 19  
 Kimball, T.R., 721  
 Kimura, R., 4:E17  
 Kimura, T., 3:E13  
 Kingdon, E., 651  
 Kingma, H.A., 330  
  
 Kirmizis, D., 544  
 Kiroychewa, M.K., 424  
 Kishimoto, N., 3:E13  
 Kjellstrand, C.M., 90  
 Ko, P.-J., 74  
 Ko, Y.-L., 74  
 Ko, Y.-S., 74  
 Kobayashi, M., 433  
 Kocaman, O., 854  
 Kohlmeier, L.A., 5:xlix  
 Koivisto, A.-M., 809  
 Koo, J.-R., 1109  
 Kopple, J.D., 671  
 Korejwo, G., 260  
 Korevaar, J.C., 891  
 Kox, W.J., 444  
 Koyama, A., 433  
 Krämer, B.K., 10  
 Krediet, R.T., 891  
 Kretschmer, U., 342  
 Krivitski, N., 5:E21  
 Kühn, K., 358  
 Kum, L.C.C., 801  
 Kumagai, H., 454  
 Kumar, S., 5:E19  
 Kuppasamy, T.S., 365  
 Kurella, M., 868  
 Kurokawa, K., 1024  
 Kutlay, S., 6:E25  
 Kuypers, D., 5:E24  
  
 Lafage-Proust, M.-H., 566  
 Lafont, T., 140  
 Lager, D.J., 147  
 Laegreid, I.K., 485  
 Lajoie, G., 2:E8  
 Lameire, N., 817  
 Lamerton, E.H., 531  
 Landray, M.J., 244  
 Langefeld, C.D., 796  
 Langman, C., 558  
 Lappin, D.W.P., 636  
 Larson, T.S., 112  
 Lasic, L., 3:E12  
 Lau, C.S., 269  
 Lau, J., 1  
 Launay-Vacher, V., 209  
 Law, M.-C., 712  
 Lederer, E., 2:E5  
 Lee, H.S., 19  
 Lee, T., 1008  
 Lee, W.-C., 1091  
 Lee, Y.-S., 74  
 Lefante, J.J., 629  
 Lehn, R.S., 671  
 Lehnert, S.D., 415  
 Leonard, M., 566  
 Leontini, M., 544  
 Lerut, E., 5:E24  
 Leung, N., 147  
 Levey, A.S., 607, 900  
 Levi, M., 154  
 Levin, A., 572

- Levy, J., 103  
 Lewis, T.H., 5:xlix  
 Li, C.S., 910  
 Li, P.K.-T., 712  
 Li, S., 464  
 Lian, J.-D., 1091  
 Liberopoulos, E., 223  
 Liefeldt, L., 923  
 Lim, G., 154  
 Lin, F., 37  
 Lin, S.-H., 304  
 Lindberg, J.S., 877  
 Lindsay, R.M., 5:E21  
 Lindschau, C., 286  
 Lip, G.Y.H., 244  
 Liu, E., 671  
 London, G., 572  
 Lopau, K., 538  
 Lord, G.M., 4:E18  
 Lorenz, M., 1065, 1098  
 Lorenzo, V., 999  
 Luft, F.C., 286  
 Lui, S.-F., 712  
 Luño, J., 846  
 Lurie, N., 386
- MacRae, J.M., 5:E21  
 Magen, D., 600  
 Mahmoud, I.M., 131  
 Mak, Y.F., 580  
 Mäkelä, S., 809  
 Makino, H., 1:E1  
 Malatino, L.S., 479  
 Mallamaci, F., 479  
 Malluche, H.H., 558  
 Mandel, H., 600  
 Mangat, S., 3:xlvi  
 Manolis, E., 140  
 Marino, N.D., 3:E12  
 Markell, M., 953  
 Markowitz, G.S., 186, 388  
 Marshall, M.R., 696  
 Martin, K.J., 558  
 Martín, M., 999  
 Martin-Malo, A., 685  
 Marwick, T.H., 45  
 Masaki, H., 3:E13  
 Mase, K., 433  
 Massry, S.G., 558  
 Massy, Z., 572  
 Matsuda, M., 5:E22  
 Matsukura, H., 3:E11  
 Matsuyama, T., 918  
 Matsuzawa, N., 4:E17  
 Mauel, R., 399  
 Maung, H.M., 877  
 McAllister, C.J., 671  
 McCann, L., 558  
 McCarron, D.A., 572  
 McCarthy, J.T., 558  
 McCloskey, D.J., 502  
 McCullough, K.P., 1014
- McDonald, S.P., 492, 696  
 McGlynn, F.J., 244  
 McLellan, D.H., 296  
 Meehan, S.M., 164  
 Mehls, O., 558  
 Mellow, E., 3:E12  
 Melnikov, V.Y., 405  
 Melzer, C., 444  
 Memmos, D., 544  
 Mendelssohn, D.C., 930  
 Mengel, M., 286  
 Mercanoglu, F., 854  
 Merkel, S., 286  
 Meroni, P.L., 28  
 Meyer, K.B., 900  
 Michelis, M.F., 3:E12  
 Mikhailidis, D.P., 589  
 Milionis, H.J., 589  
 Milliner, D.S., 277  
 Minutolo, R., 782  
 Mir, S., 727  
 Mitchell, R.L., 752  
 Mitra, S., 531  
 Mitsnefes, M.M., 721  
 Miya, K., 3:E11  
 Miyaji, K., 454  
 Miyamori, T., 5:E20  
 Miyata, T., 1024  
 Miyawaki, T., 3:E11  
 Moe, S.M., 552  
 Mok, C.C., 269  
 Monk, R.D., 663  
 Moon, K.C., 19  
 Morgera, S., 444  
 Mori, Y., 3:E13  
 Moriguchi, R., 1030  
 Morita, Y., 1:E1  
 Moroni, G., 28  
 Moss, A.H., 172  
 Mülleijans, R., 10  
 Muller, D.N., 286  
 Müller, J.M., 444  
 Muntner, P., 629  
 Muscogiuri, P., 471  
 Mustonen, J., 809
- Nadasdy, G., 757  
 Nadasdy, T., 757  
 Nagata, T., 3:E13  
 Nakabayashi, K., 4:E17  
 Nakamoto, H., 1056  
 Nakanishi, T., 1030  
 Nanami, M., 1030  
 Nangaku, M., 1024  
 Narita, M., 433  
 Navis, G., 966  
 Nemati, E., 103  
 Netzer, K.-O., 538  
 Neumann, H.P.H., 358  
 Neumayer, H.-H., 444, 923  
 Newman, A.B., 861  
 Newman, D.J., 244  
 Ng, W.L., 269
- Ng, Y.-Y., 2:E6  
 Niemir, Z.I., 983  
 Nilsen, T.I.L., 485  
 Nishimoto, N., 1:E1  
 Noonan, S.J., 350  
 Norby, S., 277  
 Nose, A., 3:E13
- Oberbauer, R., 1065  
 O'Brien, K., 933  
 Odamaki, M., 454  
 O'Donoghue, D.J., 531  
 Ofiaz, H., 854  
 Ohkawa, S., 454  
 Ohta, S., 5:E20  
 Ohtsubo, K., 3:E11  
 Øien, C., 485  
 Ojeda, R., 685  
 Okada, H., 1056  
 Okazaki, K., 3:E13  
 Okino, T., 1:E1  
 Olejniczak, P., 983  
 Olgaard, K., 558  
 O'Shaughnessy, E.A., 1071  
 Osteoporosis Work Group, 566  
 Otaki, Y., 1030  
 Ott, S., 566  
 Otto, E., 358
- Pallas, G., 161  
 Pandeya, S., 5:E21  
 Pang, J.-H.S., 74  
 Panuccio, V., 479  
 Panzeri, P., 28  
 Papageorgiou, A.A., 589  
 Parikh, C.R., 405, 415  
 Park, J.-K., 286  
 Parker, R.C., 607  
 Pasternack, A., 809  
 Pehlivanidis, A.N., 589  
 Pendse, S., 772  
 Penne, E.L., 61  
 Peppia, M., 690  
 Pereira, D., 313  
 Péron, J.-M., 617  
 Pesavento, T.E., 3:E10  
 Petronis, J.B., 1104  
 Piette, J.-C., 617  
 Plaisier, E., 617  
 Polkinghorne, K.R., 85, 696  
 Pollock, C.A., 61  
 Pond, G.R., 112  
 Pons, F., 161  
 Ponticelli, C., 28  
 Port, F.K., 1014  
 Pourrat, J., 617  
 Powe, N.R., 900  
 Preston, E., 103  
 Psaty, B.M., 861  
 Purdie, D.M., 492  
 Pusey, C.D., 4:E18  
 Puttinger, H., 1098

- Quaglini, S., 28  
 Qualls, C., 154  
  
 Rachima, C.M., 2:E3  
 Radhakrishnan, J., 388  
 Radtke, M., 485  
 Raes, A., 399  
 Raftery, M.J., 502  
 Raggi, P., 572  
 Raj, D.S.C., 154  
 Raja, R., 2:E9  
 Ravazzolo, R., 727  
 Reijngoud, D.-J., 330  
 Renke, M., 260  
 Rich, S.S., 796  
 Risler, T., 10  
 Ritz, E., 983  
 Riva, P., 28  
 Roberts, M.A., 197  
 Rodriguez, M., 566  
 Rodriguez, P., 424  
 Romundstad, P., 485  
 Ronco, P., 617  
 Rossini, M., 4:xlvi  
 Rostaing, L., 140, 617  
 Roubenoff, R., 607  
 Roufosse, C., 4:E18  
 Rubens, M., 313  
 Rudolph, B., 923  
 Rufino, M., 999  
 Rule, A., 112  
 Rumpsfeld, M., 492  
 Rutkowski, B., 260  
 Rutkowski, P., 260  
 Rydel, J.J., 164  
  
 Sagar, V., 2:E5  
 Sahadevan, M., 1071  
 Saito, A., 1024  
 Saito, H., 1:E2  
 Saito, K., 5:E20, 1024  
 Sakuma, T., 1:E2  
 Salusky, I.B., 558  
 Sanderson, J.E., 801  
 Santamaria, R., 685  
 Sarnak, M.J., 1  
 Sato, H., 1:E2  
 Sato, K., 1:E2  
 Sato, T., 1:E2  
 Sawa, N., 733  
 Sawyers, E.S., 120  
 Schweiser, H.H., 4:E18  
 Scholey, J.W., 2:E8  
 Schollmeyer, P., 10  
 Schramm, L., 538  
 Schulman, G., 933  
 Sea, M.M.-M., 712  
 Seida, A., 1:E1  
 Sengül, S., 6:E25  
 Serratrice, J., 3:E14  
 Sertcelik, A., 6:E25  
 Sessa, A., 1:xliv  
  
 Shah, R., 1071  
 Shah, S., 2:E4  
 Shanahan, C.M., 572  
 Sharples, E., 502  
 Sharples, E.J., 313  
 Sheaf, M., 2:E4, 5:E19  
 Sheha, G.E., 131  
 Shelly, M.A., 663  
 Shimizu, Y., 433  
 Shimojo, H., 5:E22  
 Shlipak, M., 37  
 Shlipak, M.G., 861, 868  
 Short, L., 45  
 Shrestha, S.M., 3:E15  
 Shu, K.-H., 1091  
 Siamopoulos, K., 223  
 Siddiqui, S., 763  
 Silkens, J.R., 1071  
 Silver, J.M., 558  
 Simonini, P., 28  
 Singh, A., 3:xlvi  
 Singh, A.K., 772  
 Singh, G.R., 254  
 Sinnott, P.J., 502  
 Sirken, G., 2:E9  
 Siscovick, D., 861  
 Sitter, T., 4:E16  
 Sklar, A.H., 705  
 Skogen, J., 1071  
 Slatopolsky, E.M., 558  
 Sloand, J.A., 663  
 Slowinski, T., 444  
 Smit, A.J., 966  
 Smogorzewski, M.T., 558  
 Snyder, J.J., 1071  
 Sobh, M.A., 131  
 Sobottke, V., 444  
 Sockeel, P., 161  
 Soejima, A., 4:E17  
 Soma, J., 1:E2  
 Song, X., 861  
 Sonomura, K., 3:E13  
 Soriano, S., 685  
 Spector, D.A., 1104  
 Speiser, W., 1098  
 Spiegel, P.J., 3:E12  
 Sprague, S.M., 566, 877  
 Stegall, M.D., 112  
 Stehman-Breen, C., 37, 566, 861  
 Stein, H., 983  
 Stellaard, F., 330  
 Stern, P., 566  
 Stevens, P.E., 825  
 Strippoli, G.F.M., 197  
 Sugahara, S., 1056  
 Sugimori, H., 5:E20  
 Summers, S., 313  
 Sunder-Plassmann, G., 1098  
 Suzuki, H., 1056  
 Suzuki, S., 433  
 Swartz, R.D., 172  
 Sweny, P., 651  
  
 Swiader, L., 3:E14  
 Symeonidis, A.N., 589  
 Szeto, C.C., 801  
  
 Tagami, T., 733  
 Takahashi, H., 433  
 Takaichi, K., 733  
 Takamitsu, Y., 1030  
 Takei, R., 733  
 Takemoto, F., 733  
 Tang, M.-J., 1091  
 Tanizawa, T., 3:E11  
 Tee, J.B., 296  
 Thébault, S., 617  
 Thomas, M.C., 1113  
 Thompson, B.C., 651  
 Thorp, M.L., 927  
 Thuringham, R.C., 2:E4  
 Tibballs, J., 651  
 Ting, G., 90  
 Tobar, A., 2:E3  
 Tokoro, T., 3:E13  
 Tokuda, T., 5:E22  
 Torres, A., 999  
 Townend, J.N., 244  
 Trachtman, H., 976  
 Trevitt, R., 502  
 Tripepi, G., 479  
 Tripepi, R., 479  
 Tsai, T.-J., 1047  
 Tsang, D.N.C., 910  
 Tsia, D.-M., 2:E7  
 Turgut, F., 854  
 Tuttle, K.R., 5:xlx  
 Tveit, D.P., 120  
 Twardowski, Z.J., 90  
 Tylicki, L., 260  
  
 Ubara, Y., 733  
 Uchiyama-Tanaka, Y., 3:E13  
 Uhlin, K.L., 607  
 Umeda, Y., 3:E13  
 Umemura, S., 3:E13  
 Unruh, M.L., 900  
 Uribarri, J., 690  
  
 Vaheri, A., 809  
 Vaithilingam, I., 85  
 Van Biesen, W., 817  
 van Burik, J.-A., 394  
 Vandekerckhove, K., 399  
 van Giersbergen, P.L.M., 923  
 Vanholder, R., 817  
 Vanrenterghem, Y., 5:E24  
 van Son, W.J., 966  
 van Ypersele de Strihou, C., 1024  
 Varagunam, M., 502  
 Vargas-Hein, O., 444  
 Varosy, P.D., 37  
 Vascular Calcification Work Group,  
 572  
 Veeneman, J.M., 330



- Ventura, D., 28  
 Vernaglione, L., 471  
 Vittinghoff, E., 37  
 Vivian, L., 624  
 Vlassara, H., 690  
 Volk, T., 444  
 Vupputuri, S., 629
- Wada, J., 1:E1  
 Wada, T., 5:E20  
 Wadhwa, N.K., 67  
 Wagenknecht, L.E., 796  
 Walde, T., 923  
 Waldek, S., 531  
 Waldherr, R., 983  
 Walle, J.V., 399  
 Wang, A.Y.-M., 712  
 Wang, S., 19  
 Wang, Y., 4:xlvi  
 Wanner, C., 538  
 Wasserstein, M., 186  
 Watkinson, A., 651  
 Webb, M., 825  
 Webster, A.C., 752  
 Wegner, B., 444  
 Weigel, G., 1098  
 Weiler, G., 624  
 Weiller, P.-J., 3:E14  
 Weintraub, A., 1  
 Weisinger, J., 566  
 Weiss, L.S., 976  
 Wells, M., 5:E23  
 Wen, M.-S., 1040
- Wenger, N.K., 37  
 Wheeler, D., 2:xlvi  
 Wheeler, D.C., 244, 651  
 Whelton, P.K., 629  
 Widerøe, T.-E., 485  
 Wilks, T.S., 927  
 Williams, A.W., 90  
 Williams, M.A., 705  
 Williams, M.E., 877  
 Wilson, K., 147  
 Witt, S.A., 721  
 Wolfe, R.A., 1014  
 Wolffenbuttel, B.H.R., 966  
 Wolzt, M., 1098  
 Wong, H., 624  
 Wong, J.T.H., 801  
 Wong, K.M., 910  
 Wong, S.H.S., 580  
 Wong, W.S., 269  
 Woo, J., 712  
 Woo, K.S., 801  
 Wood, G.N., 531  
 Woredek, Y., 90  
 Wörmle, M., 4:E16  
 Wu, E.B., 801  
 Wu, K.-D., 1047  
 Wu, M.-J., 1091
- Yaffe, K., 868  
 Yamada, A., 4:E17  
 Yamagata, K., 433  
 Yamahana, J., 5:E20  
 Yamahara, H., 3:E13
- Yamamoto, K., 5:E22  
 Yang, A.-H., 2:E6  
 Yang, C.-R., 1091  
 Yang, M.-T., 2:E7  
 Yang, W.-C., 2:E6  
 Yaqoob, M., 5:E19  
 Yaqoob, M.M., 313, 502  
 Yata, N., 918  
 Yazaki, M., 5:E22  
 Yegenaga, I., 817  
 Yekeler, E., 854  
 Yen, C.-J., 1047  
 Yim, C.W., 269  
 Ying, K.Y., 269  
 Yip, G.W.K., 801  
 Yokota, M., 733  
 Yokoyama, H., 5:E20  
 Yonemura, K., 53  
 Yoon, J.-W., 1109  
 Yorioka, N., 572  
 Yoshida, K., 5:E20  
 Yoshino, T., 1:E1  
 Young, A., 825  
 Yu, C.M., 801
- Zäuner, I., 10, 358  
 Zawada, E.T. Jr., 943  
 Zdrojewski, Z., 260  
 Zelikovic, I., 600  
 Zimmermann, J., 538  
 Zoccali, C., 479, 782  
 Zuckermann-Becker, H., 444

## SUBJECT INDEX

Articles appearing on **AJKD ELECTRONIC PAGES** are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (May 2004) are preceded, by S1:.

*Notice to Readers*

Please be advised that the numbering of online-only items in the print tables of contents of the January through June 2004 issues of **AJKD** and in this index is inconsistent with the numbering of those items online. Please refer to [www.ajkd.org](http://www.ajkd.org) for the appropriate numbering of online-only items, which is how these items are cited in *Index Medicus/MEDLINE/PubMed*. We regret the inconvenience.

Abruptio placenta, kidney disease during pregnancy and, 415-423  
 Access, vascular. *See* Vascular access  
 ACD-A (Anticoagulant Citrate Dextrose Formula A), for regional anticoagulation in CVVHDF, 67-73  
 ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors  
 N-Acetylcysteine, for radiocontrast nephropathy prevention, 1-9, 801-808

Acute renal failure (ARF)  
 after kidney transplantation, 1136  
 ApoE polymorphisms in renal disease and, 223-233  
 apolipoprotein E and, 223-233  
 with casts, eliciting a cellular reaction, 1138-1141  
 Cochrane Renal Group report, 752-756  
 due to sepsis/systemic inflammatory response syndrome, 817-824

- extended dialysis, efficacy and cardiovascular tolerance of, 342-349
- in pediatric MCD, glomerular basal membrane changes and, 399-404
- posttransplant
- core nephrology curriculum, 1136
  - effect of ACE inhibitor and ATII blockers on, 1065-1070
  - restless legs syndrome in dialysis patients and, 763-771
  - transient, with hematuria in SLE patient with warfarin coagulopathy, 757-760
- Acute tubular necrosis (ATN)
- with casts, in child, 1138-1141
  - urinary interleukin-18 as marker for, 405-414
- Adiponectin, in peritoneal dialysis patients, 1047-1055
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Advanced care planning, for kidney disease, 173-175
- Advanced glycation end products (AGEs)
- in chronic allograft nephropathy, 154-160
  - and inflammation in renal failure, 690-695
  - in inflammatory state of chronic renal failure, 690-695
  - in kidney transplant patients, 966-975
  - reduction, ultrapure dialysate for, 1024-1029
- African-Americans
- kidney transplantation rates, 386-387
  - nephrotic-range proteinuria in, 933-938
  - pediatric kidney transplant recipients with FSGS, 1082-1090
  - predialysis vascular access management, 1008-1013
  - referrals for kidney transplantation, 350-357
- Age/aging
- as baseline predictor of peritoneal transport status, 492-501
  - end-stage renal disease incidence in Japan and, 433-443
- AGEs. *See* Advanced glycation end products
- Alanine aminotransferase, in HCV-infected transplant recipients, 131-139
- Albumin, serum
- in chronic kidney disease, 244-253
  - influence on CRP in long-term hemodialysis, 471-478
  - prediction of vascular events and mortality in ESRD and, 61-66
- Albuminuria. *See also* Proteinuria
- in Australian aborigines, 254-259
  - in hantavirus-induced nephritis, 809-816
- Allergic angitis, oculorenal manifestations in, 209-222
- Allografts. *See* Grafts
- Ambulatory blood pressure monitoring, in chronic kidney disease, S1:252-261
- Amino acids, protein kinetics in hemodialysis patients and, 330-341
- Amphetamine use in hypertensive men, mild kidney function decline risk in, 629-635
- Amyloidosis
- dialysis-related, ApoE polymorphisms and, 223-233
  - immunoglobulin-derived, with immunoglobulin  $\gamma$ -heavy chain fragment, 5:E22
- Anemia, left ventricular morphology in African Americans with kidney dysfunction and, 836-845
- Angio-arteriogenesis in enlarged polycystic liver, intravascular embolization therapy for, 733-738
- Angiogenesis in enlarged polycystic liver, intravascular embolization therapy for, 733-738
- Angiotensin converting enzyme inhibitors (ACE inhibitors) with AT-1 receptor antagonists, for primary glomerulonephritis, 260-268
- for chronic kidney disease, S1:38-39, S1:183-205
  - effect on early posttransplant kidney graft function, 1065-1070
- Angiotensin receptor blockers (ARBs)
- with ACE inhibitors, for primary glomerulonephritis, 260-268
  - for chronic kidney disease, S1:38-39, S1:183-205
  - early posttransplant kidney graft function and, 1065-1070
  - residual renal function in CAPD patients and, 1056-1064
- Anorexia of renal disease, palliative care for, 179
- Antibiotic therapy, for peritonitis vs. peritoneal dialysis catheter removal, 103-111
- Anti-CD20 monoclonal antibody, for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia, 5:E24
- Anticoagulant Citrate Dextrose Formula A (ACD-A), for regional anticoagulation in CVVHDF, 67-73
- Anti-glomerular basement membrane antibody disease, oculorenal manifestations in, 209-222
- Antihypertensive therapy
- for diabetic kidney disease, S1:142-158
  - for extracellular volume control in CKD, 782-795
  - for hypertension with chronic kidney disease, 65, 120-141, S1:36-37
  - controlled trials, design and conduct of, S1:63-64
  - effect on progression, S1:59
  - preferred agents, 66, S1:59-61
  - proteinuria and, S1:66-67
  - rationale for, S1:65-73
  - strategies/targets for, S1:61-62
  - for kidney disease in renal transplant recipient, S1:176-182
  - for nondiabetic kidney disease, S1:159-175
  - residual renal function in CAPD patients and, 1056-1064
- Antineutrophil cytoplasmic autoantibody specific for proteinase 3 (PR3-ANCA), in shunt nephritis, 5:E20
- Antiphospholipid antibodies, chronic renal insufficiency in lupus nephritis and, 28-36
- Apolipoprotein E (ApoE), renal disease and, 223-233
- ARBs. *See* Angiotensin receptor blockers
- ARF. *See* Acute renal failure
- Argpyrimidine, in transplant recipients with chronic allograft nephropathy, 154-160
- Arteriovenous fistula (AVF)
- associated with high-output cardiac failure, 5:E21
  - maintenance hemodialysis survival and, 999-1007
  - predialysis management of, 1008-1013
  - prevalence, in New Zealand hemodialysis population, 696-704
  - transarterial embolization, delayed complications of, 1109-1112
- Arteriovenous malformation, delayed complications from transarterial embolization, 1109-1112
- Asians
- end-stage renal disease incidence in, 433-443



- peritoneal dialysis patients, hyperphosphatemia in, 712-720
- urinary transition tract transitional cell carcinoma after kidney transplantation, 1091-1097
- Atherosclerosis**
- EBCT coronary artery calcification, correlation with coronary artery angiography, 313-319
- risk, apolipoprotein E polymorphisms in renal failure and, 223-233
- vascular calcification, in chronic kidney disease, 572-579
- ATN. See Acute tubular necrosis**
- Atorvastatin**, influence on CRP in long-term hemodialysis, 471-478
- Attention**, temporal effects of dialysis in ESRD, 705-711
- Australian aborigines**, kidney volume, blood pressure and albuminuria in, 254-259
- Autoimmune diseases**, systemic, oculorenal manifestations in, 209-222
- Autosomal dominant polycystic kidney disease (ADPKD)**
- in children, phenotypic heterogeneity in, 296-303
- early hyperfiltration in, 624-628
- endothelial dysfunction and increased carotid intima-media thickness in, 854-860
- intractable pain-related, thorascopic renal denervation for, 161-163
- intravascular embolization therapy for enlarged liver, 733-738
- Autosomal recessive renal proximal tubulopathy**, hypercalciuria and, 600-606
- AVF. See Arteriovenous fistula**
- Bariatric surgery**, for weight management for obese kidney transplant recipients, 943-952
- Basement membrane disease risk**, in living donors, 508-530
- Behçet's disease**, oculorenal manifestations in, 209-222
- Benazepril**, with losartan, for primary glomerulonephritis, 260-268
- Biochemical markers**, for renal osteodystrophy, 558-565
- Biopsy**
- bone, in renal osteodystrophy, 558-565
- renal allograft, core curriculum in nephrology, 1116-1135
- transjugular renal, for high-risk patients, 651-662
- Birth certificate data**, on kidney disease during pregnancy, 415-423
- Blacks. See African-Americans**
- Blood pressure. See also Hypertension**
- ambulatory monitoring in chronic kidney disease, S1:252-261
- in Australian aborigines, 254-259
- classification and management of, S1:42-44
- effect on kidney transplantation outcome, 1071-1081
- in Gitelman's syndrome, 304-312
- measurement in adults, S1:34-35, S1:92-100
- target, achievement in chronic kidney disease, 782-795
- Blood transfusion**, for dialysis patients, pure red cell aplasia and, 464
- Blood urea nitrogen (BUN)**, sepsis/SIRS patients developing ARF, 817-824
- Body mass index (BMI)**, as baseline predictor of peritoneal transport status, 492-501
- Body size**, as baseline predictor of peritoneal transport status, 492-501
- Bone biopsy**, in renal osteodystrophy, 558-565
- Bone density classification of osteoporosis**, in chronic kidney disease, 566-571
- Bone disease**, after kidney transplantation, 1137
- Bone fracture risk**, in hemodialysis, ApoE polymorphisms and, 223-233
- Bone marrow examination**, assessment of pure red cell aplasia in US dialysis patients, 464
- Bone metabolism**, management in chronic kidney disease, 552-557
- Bone turnover abnormalities**, in renal osteodystrophy, diagnosis, assessment and treatment of, 558-565
- Borrelia burgdorferi infection**, with secondary membranoproliferative glomerulonephritis, 544-551
- Bosentan**, for secondary pulmonary hypertension, 923-926
- BUN (blood urea nitrogen)**, sepsis/SIRS patients developing ARF, 817-824
- Calcimimetic agents**, for renal osteodystrophy, 558-565
- Calciophylaxis**, intravenous sodium thiosulfate for, 1104-1108
- Calcium-containing dialysate**, for regional anticoagulation in CVVHDF, 67-73
- Calcium-phosphorus metabolism**, cardiac calcification in renal patients and, 234-243
- CAPD. See Continuous ambulatory peritoneal dialysis**
- Carbonyl stress**
- chronic renal transplant dysfunction and, 966-975
- marker, reduction by ultrapure dialysate, 1024-1029
- in transplant recipients with chronic allograft nephropathy, 154-160
- N-Carboxymethyllysine**, measurement in inflammatory state of chronic renal failure, 690-695
- Cardiac calcification**, in renal patients, 234-243
- Cardiac failure**, high-output, arteriovenous fistula associated with, 5:E21
- Cardiac function**, in children after renal transplantation, 721-726
- Cardiac hypertrophy**, in children after renal transplantation, 721-726
- Cardiac output**, high, arteriovenous fistula-associated with, 5:E21
- Cardiac variant Fabry disease**, renal involvement in, 164-171
- Cardiopulmonary resuscitation (CPR)**, for kidney disease, 173-175
- Cardiovascular calcifications**, as cardiovascular risk factor in hemodialysis patients, 479-484
- Cardiovascular disease (CVD)**
- in chronic kidney disease, 244-253, S1:16-19
- increased risk of, S1:50-51
- as independent risk factor, S1:51-53
- initiation/progression of, S1:50
- risk factors in, S1:50-51
- effects of statins versus untreated dyslipidemia on serum uric acid levels, 589-599
- inflammatory state of chronic renal failure and, 690-695
- mortality
- cardiac calcification in renal patients and, 234-243

- obese kidney transplant recipients and, 943-952  
 prediction, pretransplantation levels of CRP and, 502-507  
 troponin T levels in chronic kidney disease and, 846-853  
 posttransplant  
   in children, 721-726  
   core nephrology curriculum, 1135-1136  
 risk  
   adiponectin in peritoneal dialysis patients and, 1047-1055  
   lowering of blood pressure and, 782-795  
   slowing CKD progression and, S1:67-70  
   in women, small changes in creatinine and, 37-44  
 Carotid intima-media thickness  
   in autosomal dominant polycystic kidney disease, 854-860  
   in chronic kidney disease, effect of lipid lowering on, 45-52  
 Cataracts, in Lowe syndrome, 538-543  
 Catheters  
   peritoneal dialysis, removal for acute peritonitis, 103-111  
   placement in left internal jugular vein, 365-367  
   usage in New Zealand hemodialysis population, 696-704  
 Caucasians, racial differences in referral for renal transplantation, 350-357  
 Cell proliferation, restenosis after PTA and, 74-84  
 Centers for Medicare and Medicaid Services (CMS), survival benefit for higher dialysis doses in women, 1014-1023  
 Children  
   abnormal cardiac function after renal transplantation, 721-726  
   acute tubular necrosis with casts, 1138-1141  
   with ARF and MCD, glomerular basal membrane changes and, 399-404  
   autosomal dominant polycystic kidney disease, phenotypic heterogeneity in, 296-303  
   chronic kidney disease in, S1:40-41  
   with hypertension and chronic kidney disease, S1:223-229  
   impact of unilateral nephrectomy on, 508-530  
   kidney transplant recipients, with FSGS, differential effect of race on, 1082-1090  
   membranoproliferative glomerulonephritis with few urinary abnormalities, 918-922  
   renal osteodystrophy in, 558-565  
   steroid-resistant nephrotic syndrome, NPHS2 gene mutations and, 727-732  
 Chlamydia seropositivity, mortality and graft outcome in transplant recipients and, 502-507  
 Chlorambucil, for idiopathic focal segmental glomerulosclerosis, 10-18  
 Chloride channel gene mutation, in autosomal recessive renal proximal tubulopathy, 600-606  
 Cholesterol, in estimating apolipoprotein B-containing lipoproteins, 320-329  
 Chronic allograft nephropathy (CAN)  
   advanced glycation end products and, 966-975  
   core curriculum in nephrology, 1116-1135  
   impact of hepatitis C virus viremia on, 131-139  
   increased advanced glycation end products and oxidative stress in, 154-160  
   pretransplant CRP levels and, 502-507  
 Chronic kidney disease (CKD)  
   ACE inhibitors and angiotensin receptor blockers for, S1:38-39  
   adverse effects with low molecular weight heparin and, 531-537  
   after kidney transplantation, 1136  
   antihypertensive therapy  
     goals of, S1:33  
     strategies/targets for, S1:61-62  
   apolipoprotein E and, 223-233  
   apolipoprotein E polymorphisms in renal disease and, 223-233  
   bone metabolism management in, 552-557  
   cardiovascular disease in, S1:16-19  
   cardiovascular events in women with heart disease and, 37-44  
   in children, S1:40-41  
   competing risks in, S1:62-63  
   definition of, S1:45  
   diuretics in, S1:39-40  
   early changes in daily hemodialysis, 90-102  
   effect of lipid lowering on atherosclerotic burden, 45-52  
   evaluation of, S1:33-34, S1:74-91  
   frailty in elderly persons with, 861-867  
   glycoxidation and inflammation in, 690-695  
   with heart valve calcifications, survival and CV mortality and, 479-484  
   with hypertension, S1:16-19  
     dietary/lifestyle changes in adults, S1:115-119  
     evaluation of, S1:33-34  
     high-risk groups, recommendations for, S1:71-73  
     low-risk groups, recommendations for, S1:71-73  
     risk stratification, S1:71  
     self-management behavior education, S1:107-114  
     self-management behavior for, S1:36  
   inflammation, endothelial dysfunction and platelet activation in, 244-253  
   initiation and progression of, S1:44  
   in lupus nephritis, antiphospholipid antibodies and, 28-36  
   NKF-K/DOQI guidelines. *See* K/DOQI Clinical Practice Guidelines  
   osteoporosis in, 566-571  
   physical and sexual function in women, 868-876  
   pre-existing, effect of N-acetylcysteine for radiocontrast nephropathy prevention, 1-9  
   progression, S1:20, S1:55-61  
     hypertension and, S1:55-58  
     proteinuria and, S1:58-59  
     RAS and, S1:59  
     slowing, antihypertensive drugs and, 67-70, S1:59  
   proteinuria, importance of, S1:45-47  
   resistance training to reduce malnutrition-inflammation complex syndrome in, 607-616  
   risk after illicit drug use in hypertensive men, 629-635  
   risk factors for, S1:44  
   risk stratification in, S1:47-48  
   secondary hyperparathyroidism, doxercalciferol suppression of PTH in, 877-890

- stages of, 46, 48, S1:45
- troponin T levels in, 846–853
- types, prevalence of, 46, S1:45
- unreferred, longitudinal study of, 825–835
- Chronic Renal Impairment in Birmingham Study (CRIB), inflammation, endothelial dysfunction and platelet activation in chronic kidney disease, 244–253
- Churg-Strauss syndrome, oculorenal manifestations in, 209–222
- Citrate anticoagulation, for CVVHDF using calcium-containing dialysate, 67–73
- CKD. *See* Chronic kidney disease
- CMS (Centers for Medicare and Medicaid Services), survival benefit for higher dialysis doses in women, 1014–1023
- Cocaine use, in hypertensive men, mild kidney function decline risk in, 629–635
- Cochrane Renal Group
  - meta-analysis of randomized controlled trials for diffuse proliferative lupus nephritis, 197–208
  - randomized controlled trial report, 752–756
- Cognitive functioning, temporal effects of dialysis in ESRD, 705–711
- Cohort studies, illicit drug use in hypertensive men, mild kidney function decline risk in, 629–635
- Collapsing glomerulopathy, in adult Still's disease, 5:E19
- Combination therapy, for primary glomerulonephritis, 260–268
- Communication issues, end-of-life care, 175–176
- Computed tomography, protein requirements for hemodialysis and, 454–463
- Constipation of renal disease, palliative care for, 179
- Continuous ambulatory peritoneal dialysis (CAPD)
  - apolipoprotein E polymorphisms in renal disease and, 223–233
  - calciphylaxis, intravenous sodium thiosulfate for, 1104–1108
  - hyperphosphatemia in Chinese patients, 712–720
  - for infectious peritonitis, transperitoneal water transport and, 485–491
  - intradermal hepatitis B vaccination in, 910–917
  - residual renal function, effects of angiotensin II receptor blockers on, 1056–1064
- Continuous venovenous hemodiafiltration (CVVHDF), regional citrate anticoagulation using calcium-containing dialysate, 67–73
- Continuous venovenous hemofiltration (CVVH), in critically ill patients, efficacy and cardiovascular tolerability of, 342–349
- Contrast nephropathy, Cochrane Renal Group report, 752–756
- Contrast nephropathy prevention, *N*-acetylcysteine for, 1–9, 801–808
- Core nephropathy curriculum, palliative care, 172–185
- Corneal abnormalities, in systemic autoimmune diseases, 209–222
- Coronary artery angiography, correlation with EBCT for coronary artery calcification measurement, 313–319
- Coronary artery calcification
  - measured by EBCT correlated with coronary artery angiography in dialysis patients, 313–319
  - in renal patients, 234–243
- Coronary heart disease. *See* Cardiovascular disease
- CPR (cardiopulmonary resuscitation), for kidney disease, 173–175
- C-reactive protein (CRP)
  - adiponectin in peritoneal dialysis patients and, 1047–1055
  - inflammatory state in chronic renal failure and, 690–695
  - in long-term hemodialysis, atorvastatin and, 471–478
  - pretransplant levels in predicting all-cause and cardiovascular mortality, 502–507
- Creatinine, serum
  - cardiovascular events in women with heart disease and, 37–44
  - in GFR estimates of health potential kidney donors, 112–119
  - sepsis/SIRS patients developing ARF, 817–824
  - weekly clearance, residual renal function in CAPD patients and, 1056–1064
- CRIB (Chronic Renal Impairment in Birmingham Study), inflammation, endothelial dysfunction and platelet activation in chronic kidney disease, 244–253
- Crossmatching, core curriculum in nephrology, 1116–1135
- CRP. *See* C-reactive protein
- Cryoglobulinemia
  - in HCV-associated MPGN, effect of antiviral therapy on, 617–623
  - oculorenal manifestations in, 209–222
- CVVH (continuous venovenous hemofiltration), in critically ill patients, efficacy and cardiovascular tolerability of, 342–349
- CVVHDF (continuous venovenous hemodiafiltration), regional citrate anticoagulation using calcium-containing dialysate, 67–73
- Cyclin-dependent kinase, in focal segmental glomerulosclerosis, podocyte proliferation and, 19–27
- Cyclin-dependent kinase inhibitors, in focal segmental glomerulosclerosis, podocyte proliferation and, 19–27
- Cyclins, in focal segmental glomerulosclerosis, podocyte proliferation and, 19–27
- Cyclophosphamide therapy
  - for diffuse proliferative lupus nephritis, 197–208
  - ovarian and testicular function preservation after, 772–781
- Cyclosporine A, for idiopathic focal segmental glomerulosclerosis, 10–18
- Cystic kidney disease, clinical and histological presentation of siblings with NPHP4 gene, 358–364
- Cytokines. *See also* specific cytokines
  - clearances, renal replacement therapy with high-cutoff hemofilters and, 444–453
  - proinflammatory, iron metabolism in HD patients and, 1030–1039
  - in Puumala hantavirus-induced nephritis pathogenesis, 809–816
- Cytotoxicity, prednisone and azathioprine for pure membranous lupus nephropathy and, 269–276

- Death certificate data, on kidney disease during pregnancy, 415-423
- Deep venous thrombosis risk, after renal transplantation, 120-130
- Delayed graft function  
after kidney transplantation, 1136  
effect of ACE inhibitor and ATII blocker therapy on, 1065-1070  
urinary interleukin-18 levels and, 405-414
- Depression, palliative care for, 180
- DEXA, in renal osteodystrophy assessment, 558-565
- Diabetes mellitus. *See also* Diabetic nephropathy  
new-onset, in transplant patients, 953-965  
peritoneal equilibrium tests in measuring glucose levels to determine intraperitoneal insulin, 927-929  
predialysis vascular access management, 1008-1013  
type 2  
risk, for living donors, 508-530  
unilateral nephrectomy in, 508-530
- Diabetic nephropathy  
apolipoprotein E and, 223-233  
apolipoprotein E polymorphisms and, 223-233  
chronic, with osteoporosis, 566-571  
Cochrane Renal Group report, 752-756  
glomeruli, gene expression profiling in, 636-650  
pharmacological therapy, 142-158, S1:37-38
- Dialysate  
calcium-containing, for CVVHDF regional anticoagulation, 67-73  
purity, effect on pentosidine plasma levels, 1024-1029
- Dialysis. *See also* specific dialysis modalities  
assessment of pure red cell aplasia in, 464  
for chronic renal failure, glycooxidation and inflammation in, 690-695  
Cochrane Renal Group report, 752-756  
initiation in undocumented aliens, 424-432  
modality selection  
cardiac calcification in renal patients and, 234-243  
empowerment of patient preference in, 930-932  
long-term decision-making factors in, 877-890  
restless legs symptoms, quality of life/survival and, 900-909  
surrogate marker for nontraditional lipoprotein subclass risk factors, 320-329
- Dialysis catheters. *See* Catheters
- Dialysis Outcomes and Practice Patterns Study (DOPPS), survival benefit for higher dialysis doses in women, 1014-1023
- Dialysis-related amyloidosis, apolipoprotein E polymorphisms and, 223-233
- Diastolic function  
during hemodialysis, tissue Doppler imaging of, 1040-1046  
impaired, in children after renal transplantation, 721-726
- Diet  
for chronic kidney disease with hypertension, S1:115-119  
sodium restriction in chronic kidney disease, 782-795  
for weight management for obese kidney transplant recipients, 943-952
- Diuretics  
achievement of target blood pressure in chronic kidney disease and, 782-795  
for chronic kidney disease, S1:39-40, S1:206-222
- Dopamine, restless legs syndrome in dialysis patients and, 763-771
- DOPPS (Dialysis Outcomes and Practice Patterns Study), survival benefit for higher dialysis doses in women, 1014-1023
- Dosage effect  
of combination therapy for primary glomerulonephritis, 260-268  
gender differences in HD mortality rates, 1014-1023
- Doxercalciferol, suppression of PTH levels in secondary hyperparathyroidism with CKD, 877-890
- Dyslipidemia with coronary heart disease, serum uric acid levels in, 589-599
- Dystroglycan, unexplained proteinuria in adulthood and, 933-938
- EBCT. *See* Electron-beam computed tomography
- Echocardiography, of left ventricular morphology in African Americans with kidney dysfunction, 836-845
- Elderly, frailty with chronic renal insufficiency, 861-867
- Electron-beam computed tomography (EBCT)  
of cardiac calcification in renal patients, 234-243  
coronary artery calcification, correlation with coronary artery angiography, 313-319
- EMBASE, meta-analysis of randomized controlled trials for diffuse proliferative lupus nephritis, 197-208
- Endothelial-dependent dilatation, in ADPKD, 854-860
- Endothelial dysfunction  
in autosomal dominant polycystic kidney disease, 854-860  
in chronic kidney disease, 244-253  
in inflammatory state of chronic renal failure, 690-695
- Endothelin, in pulmonary hypertension pathogenesis, 923-926
- Endotoxin-free dialysate, reduction of plasma pentosidine levels, 1024-1029
- End-stage renal disease (ESRD)  
CAPD patients, intradermal hepatitis B vaccination in, 910-917  
cognitive functioning, temporal effects of dialysis on, 705-711  
daily hemodialysis, early changes in, 90-102  
effect of contraindications and patient preference on modality selection, 877-890  
in hemodialysis patient, lag phenomenon and, 739-751  
in Japan, age distribution and yearly changes in, 433-443  
in living donors, 508-530  
Lowe syndrome and, 538-543  
mortality, pretransplantation CRP levels in prediction of, 502-507  
palliative care, 172-173  
prediction of vascular events and mortality in, 61-66  
racial differences in referral for renal transplantation, 350-357  
renal transplantation for, early renal insufficiency and late venous thromboembolism after, 120-130  
renin-angiotensin system blockade in, 1113-1115

- with restless legs syndrome, intravenous iron dextran therapy for, 663-670
- secondary pulmonary hypertension, Bosentan for, 923-926
- Epidemiology
  - heart disease in women, 37-44
  - illicit drug use in hypertensive men, 629-635
- Episcleritis, in systemic autoimmune diseases, 209-222
- Erythropoietin
  - low iron levels in predicting maintenance hemodialysis outcome and, 671-684
  - recombinant human, PRCA-associated with in US Medicare dialysis patients, 464-470
- ESRD. *See* End-stage renal disease
- Essential cryoglobulinemia, hepatitis C-negative therapy-resistant, rituximab for, 5:E24
- Ethical issues
  - intravascular embolization therapy for enlarged polycystic liver, 733-738
  - in withholding/withdrawal of dialysis, 181-185
- Ethnic differences, in kidney transplantation, 386-387
- Exercise
  - improvement of phosphate removal in hemodialysis and, 85-89
  - for weight management for obese kidney transplant recipients, 943-952
- Extended dialysis, in critically ill patients, efficacy and cardiovascular tolerability of, 342-349
- Extracellular volume
  - control in CKD, antihypertensive therapy for, 782-795
  - expansion, hypertension in hemodialysis and, 739-751
- Fabry disease
  - cardiac variant, renal involvement in, 164-171
  - prolonged postpartum proteinuria after preeclampsia, 186-191
- Familial renal disease risk, in living donors, 508-530
- Fanconi's syndrome, autosomal recessive renal proximal tubulopathy with hypercalciuria and, 600-606
- Fat mass, protein requirements for hemodialysis and, 454-463
- Ferritin, for ESRD with restless legs syndrome, 663-670
- Ferroportin 1 downregulation, iron levels in PMNLs of maintenance HD patients and, 1030-1039
- Ferrous sulfate, mycophenolate mofetil pharmacokinetics in transplant patients and, 1098-1103
- Fetal loss, in lupus nephritis, antiphospholipid antibodies and, 28-36
- Fibrinogen, in chronic kidney disease, 244-253
- Fistula. *See* Arteriovenous fistula
- Focal segmental glomerulosclerosis (FSGS)
  - in children, NPHS2 gene mutations and, 727-732
  - differential effect of race among pediatric kidney transplant recipients, 1082-1090
  - pathologic classification of, 368-382
    - idiopathic, cyclosporine A and chlorambucil for, 10-18
    - podocyte proliferation cell-cycle mechanisms in, 19-27
  - unexplained proteinuria in adulthood and, 933-938
  - variant, in adult Still's disease, 5:E19
- Frailty, in elderly chronic renal insufficiency patients, 861-867
- FSGS. *See* Focal segmental glomerulosclerosis
- $\alpha$ -Galactosidase A deficiency, cardiac variant, renal involvement in, 164-171
- Gene expression profiling, in glomeruli from human kidneys with diabetic nephropathy, 636-650
- Gene mutations
  - autosomal recessive renal proximal tubulopathy and, 600-606
  - clinical and histological presentation of siblings with NPHP4 gene, 358-364
  - of NPHS2, infantile steroid-resistant nephrotic syndrome and, 727-732
  - of thiazide-sensitive sodium chloride cotransporter in Gitelman's syndrome, 304-312
- GFR. *See* Glomerular filtration rate
- Giant cell arteritis, in systemic autoimmune diseases, 209-222
- Gitelman's syndrome, phenotype variability in, 304-312
- Glomerular epithelial cells, proliferation in focal segmental glomerulosclerosis cellular lesions, 19-27
- Glomerular filtration rate (GFR)
  - in autosomal dominant polycystic kidney disease, 624-628
  - decrease
    - in hypertension with chronic kidney disease, S1:79-80, S1:84
    - as risk factor for CVD in chronic kidney disease, S1:53-54
  - evaluation, in living donors, 508-530
  - late venous thromboembolism after renal transplantation and, 120-130
  - measured and estimated in healthy potential kidney donors, 112-119
- Glomeruli in diabetic nephropathy, gene expression profiling in, 636-650
- Glomerulonephritis. *See also* Membranoproliferative glomerulonephritis
  - after Lyme disease, 544-551
  - cyclophosphamide therapy, gonadal function preservation after, 772-781
  - primary, low-dose dual blockade of RAS for, 260-268
  - proliferative, treatment, meta-analysis of randomized controlled trials, 197-208
  - pure membranous lupus, prednisone and azathioprine for, 269-276
  - rapidly progressive, overlapping etiology of, 388-393
  - in situ expression of interleukin-8 and, 983-998
- Glomerulosclerosis, focal segmental. *See* Focal segmental glomerulosclerosis
- Glycemic control, for diabetic peritoneal dialysis patients, peritoneal equilibrium tests and, 927-929
- Glycoxidation, and inflammation in renal failure, 690-695
- Goodpasture's syndrome, oculorenal manifestations in, 209-222
- Grafts
  - biopsy, core curriculum in nephrology, 1116-1135
  - delayed function. *See* Delayed graft function
  - failure, posttransplant hypertension and, 1071-1081
  - predialysis management of, 1008-1013
  - rejection
    - core curriculum in nephrology, 1116-1135



- hypertension after kidney transplantation and, 1071-1081  
 survival  
 impact of hepatitis C virus viremia on, 131-139  
 pretransplant CRP levels and, 502-507  
 Granulomatosis, oculorenal manifestations in, 209-222  
 GREACE Study, subgroup analysis of, 589-599  
 Growth arrest-specific gene 6/Axl signaling, in inflammatory renal disease, 286-295  
 Growth failure, in Lowe syndrome, 538-543
- Hantavirus-induced nephritis, urinary excretion of IL-6 correlated with proteinuria in, 809-816
- HBV. *See* Hepatitis B virus
- HCV. *See* Hepatitis C virus
- HD. *See* Hemodialysis
- HDL (high-density lipoprotein), adiponectin in peritoneal dialysis patients and, 1047-1055
- Health personnel, attitudes on racial differences in renal transplantation referral, 350-357
- Health-related quality of life, restless legs symptoms in dialysis patients and, 900-909
- Heart and Estrogen/Progestin Replacement Study (HERS), cardiovascular events in women with heart disease and, 37-44
- Heart valve calcifications, survival and cardiovascular risk in hemodialysis patients and, 479-484
- $\gamma$ -Heavy chain variable region, in renal amyloidosis, 5:E22
- Hematocrit, in assessing pure red cell aplasia in dialysis patients, 464-470
- Hematuria, with transient ARF in SLE patient with warfarin coagulopathy, 757-760
- Hemodialysis (HD). *See also* Vascular access  
 apolipoprotein E polymorphisms in renal disease and, 223-233  
 assessment of left ventricular diastolic function using tissue Doppler imaging, 1040-1046  
 daily, early changes in, 90-102  
 defective regulation of iron transporters leading to iron excess in PMNLs and, 1030-1039  
 EBCT coronary artery calcification, correlation with coronary artery angiography, 313-319  
 for ESRD, IV iron dextran therapy for restless legs syndrome, 663-670  
 heart valve calcifications, survival and cardiovascular risk in, 479-484  
 high dose, associated with lower mortality in women but not men, 1014-1023  
 high-output cardiac failure, arteriovenous fistula associated with, 5:E21  
 long-term hemodialysis, atorvastatin effects on CRP, 471-478  
 maintenance  
 defective regulation of iron transporters in PMNLs, 1030-1039  
 outcome prediction, low serum iron levels and, 671-684  
 protein requirements for, 454-463  
 marked reduction in prevalence of HCV infection in, 685-689  
 metabolic response to ingested protein, 330-341  
 in New Zealand, vascular access patterns for, 696-704  
 phosphate removal improvement, time/exercise and, 85-89  
 predialysis vascular access management, 1008-1013  
 restless legs syndrome in, 763-771  
 selection, effect of contraindications and patient preference on, 877-890  
 survival, predialysis nephrologic care and arteriovenous fistula and, 999-1007  
 temporal effects on cognitive functioning in ESRD, 705-711  
 vascular access, restenosis and cell proliferation after PTA, 74-84
- Hemodialysis centers, in New Zealand, vascular access patterns for, 696-704
- Hemoglobin, left ventricular morphology in African Americans and, 836-845
- Hemolytic uremic syndrome, non-enteropathic, 976-982
- Hemorrhage, in chronic kidney disease with low molecular weight heparin, 531-537
- Hemorrhagic fever with renal syndrome, urinary excretion of IL-6 correlated with proteinuria in, 809-816
- Hemostatic activation, of inflammatory state of chronic renal failure, AGEs and, 690-695
- HEMO Study  
 extracellular volume expansion and hypertension in hemodialysis, 739-751  
 high dialysis dose associated with lower mortality in women, 1014-1023
- Henoch-Schönlein purpura nephritis, oculorenal manifestations in, 209-222
- Heparins, low molecular weight, adverse effects in chronic kidney disease, 531-537
- Hepatitis B virus (HBV)  
 intradermal vaccination, in CAPD patients, 910-917  
 risk, for living donors, 508-530
- Hepatitis C virus (HCV)  
 impact on renal graft and patient survival, 131-139  
 prevalence, marked reduction in hemodialysis patients, 685-689  
 in renal and liver transplant patients, ribavirin pharmacokinetics and, 140-146  
 risk, for living donors, 508-530  
 treatment, effect on HCV-associated cryoglobulinemic MPGN, 617-623
- Hereditary nephropathy, clinical and histological presentation of siblings with NPHP4 gene, 358-364
- Heroin use in hypertensive men, mild kidney function decline risk in, 629-635
- HERS (Heart and Estrogen/Progestin Replacement Study), cardiovascular events in women with heart disease and, 37-44
- High-cutoff hemofilters, for renal replacement therapy, 444-453
- High-density lipoprotein (HDL), adiponectin in peritoneal dialysis patients and, 1047-1055
- High-flow fistulae, mechanisms of, 5:E21
- High-risk patients, transjugular kidney biopsy for, 651-662
- Hispanics, undocumented aliens, initiation of dialysis in, 424-432
- Hospice referral, grief/bereavement support, 180-181
- Hospitalization, low serum iron levels in hemodialysis patients and, 671-684



- Human leukocyte antigens (HLAs), core curriculum in nephrology, 1116-1135
- Hypercalciuria, autosomal recessive renal proximal tubulopathy and, 600-606
- Hyperfiltration, in autosomal dominant polycystic kidney disease, 624-628
- Hyperlipidemia, in pediatric autosomal dominant polycystic kidney disease, 296-303
- Hyperoxaluria in pregnancy, outcomes and complications of, 277-285
- Hyperphosphatemia  
in Chinese peritoneal dialysis patients, 712-720  
restless legs syndrome in dialysis patients and, 763-771
- Hypertension  
after kidney transplantation, 1071-1081  
blood pressure measurement in adults, S1:92-100  
with chronic kidney disease, 42-44, S1:16-19  
antihypertensive drugs for, S1:36-37  
causes of, S1:49  
in children, S1:223-229  
control of, S1:49  
dietary sodium restriction for, 782-795  
evaluation of, S1:3-34, S1:74-91  
prevalence of, S1:48  
referrals to specialists, S1:88-89  
self-management behavior for, S1:36  
stages and, S1:48  
chronic kidney disease progression and, S1:55-58  
definition of, S1:42  
evaluation of living kidney donors and, 508-530  
in hemodialysis patient, lag phenomenon and, 739-751  
illicit drug use in men, risk for mild kidney function decline and, 629-635  
in lupus nephritis, antiphospholipid antibodies and, 28-36  
in pediatric autosomal dominant polycystic kidney disease, 296-303  
in pregnancy, outcomes and complications of, 277-285  
resistant, S1:86-88  
risk, for living donors, 508-530
- Hypertrophy, left ventricular in African Americans, 836-845
- Hypocomplementemia, membranoproliferative glomerulonephritis with few urinary abnormalities, 918-922
- Hypokalemia, in Gitelman's syndrome, 304-312
- Idiopathic focal segmental glomerulosclerosis, cyclosporine A and chlorambucil for, 10-18
- Illicit drug use, in hypertensive men, mild kidney function decline risk in, 629-635
- Immune recognition, core curriculum in nephrology, 1116-1135
- Immunoglobulin A deposits, in fibrillary glomerulopathy-immunotactoid glomerulopathy, 580-585
- Immunoglobulin A nephropathy, oculorenal manifestations in, 209-222
- Immunoglobulin B, urinary excretion, in hantavirus-induced nephritis, 809-816
- Immunoglobulin-derived amyloidosis, with immunoglobulin  $\gamma$ -heavy chain fragment, 5:E22
- Immunoglobulin  $\gamma$ -heavy chain fragment, in immunoglobulin-derived amyloidosis, 5:E22
- Immunohistochemistry, in situ expression of interleukin-8 in normal kidney and glomerulonephritis, 983-998
- Immunosuppression  
preservation of ovarian and testicular function after, 772-781  
in pure membranous lupus nephropathy, prednisone and azathioprine for, 269-276
- Immunotactoid glomerulopathy, case report of, 580-585
- Incidence, of end-stage renal disease in Japan, 433-443
- Infection  
after kidney transplantation, 1136  
Borrelia burgdorferi, with secondary membranoproliferative glomerulonephritis, 544-551  
HCV prevalence in hemodialysis patients, 685-689  
Lyme disease, postinfection glomerulonephritis and, 544-551
- Infertility, after cyclophosphamide therapy, 772-781
- Inflammation  
in chronic kidney disease, 244-253  
and glycoxidation in renal failure, 690-695  
reduction in chronic kidney disease, resistance training for, 607-616
- Initiation of dialysis, in undocumented aliens, 424-432
- Insomnia of renal disease, palliative care for, 179
- Insulin resistance, adiponectin in peritoneal dialysis patients and, 1047-1055
- Intensive care unit (ICU)  
acute renal failure development in sepsis/SIRS patients, 817-824  
efficacy and cardiovascular tolerability of extended dialysis in, 342-349
- Interferon, effect on HCV-associated cryoglobulinemic MPGN, 617-623
- Interleukin 1 $\beta$ , urinary excretion in hantavirus-induced nephritis, 809-816
- Interleukin-1 receptor antagonist, urinary excretion in hantavirus-induced nephritis, 809-816
- Interleukin-6, urinary excretion in hantavirus-induced nephritis, 809-816
- Interleukin-8, in situ expression in normal kidney and glomerulonephritis, 983-998
- Interleukin-18, urinary, as acute tubular necrosis marker, 405-414
- Intermediate density lipoprotein, calculations in estimating apolipoprotein B-containing lipoproteins, 320-329
- Intradermal hepatitis B vaccination, in CAPD patients, 910-917
- Intradialytic hypotension, transient visual loss, occipital infarction and, 5:E23
- Intradialytic symptoms, of renal disease, palliative care for, 179
- Intravascular embolization therapy, for enlarged polycystic liver, 733-738
- Iothalamate clearance, prediction of GFR in healthy potential kidney donors, 112-119
- Iron, serum  
excess in PMNLs of maintenance HD patients, 1030-1039  
outcome prediction for hemodialysis patients and, 671-684

- Iron deficiency  
  ferrous sulfate therapy in transplant patients, mycophenolic acid pharmacokinetics and, 1098–1103  
  restless legs syndrome in dialysis patients and, 763–771
- Iron therapy  
  outcome prediction for hemodialysis patients and, 671–684  
  for restless legs syndrome with ESRD, 663–670
- Iron transporters, defective regulation in PMNLs of maintenance hemodialysis patients, 1030–1039
- Kawasaki disease, oculorenal manifestations in, 209–222
- K/DOQI Clinical Practice Guidelines  
  antihypertensive therapy in CKD, S1:120–141  
  background, S1:42–64  
  comparison with European and Australian bone metabolism guidelines, 552–557  
  development of, methods used for, S1:231–251  
  dietary and lifestyle changes in adults, S1:115–119  
  education on self-management behavior, S1:107–114  
  evaluation  
    of CKD with/without hypertension, S1:74–91  
    for renal artery disease, S1:101–106  
  executive summary, S1:16–41  
  goals of antihypertensive therapy in CKD, S1:65–73  
  measurement of blood pressure in adults, S1:92–100  
  methods for evidence review and synthesis, S1:24–33  
  pharmacologic therapy  
    ACE inhibitors and ARBs for chronic kidney disease, S1:183–205  
    for diabetic kidney disease, S1:142–158  
    diuretics for chronic kidney disease, S1:206–222  
    for kidney disease in kidney transplant recipients, S1:176–182  
    for nondiabetic kidney disease, S1:159–175  
  scope of, S1:20–24  
  technical report on ambulatory blood pressure monitoring in CKD, S1:252–261  
  work group biographies, S1:262–265
- Kidney  
  function, in hepatitis C virus transplant recipients, ribavirin pharmacokinetics in, 140–146  
  gene expression profiling of human diabetic glomeruli, 636–650  
  pathology, in cardiac variant of Fabry disease, 164–171  
  ultrastructure, in cardiac variant of Fabry disease, 164–171
- Kidney biopsy, transjugular, 651–662
- Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines
- predialysis vascular access management and, 1008–1013
- Kidney donors, living  
  evaluation of, 508–530  
  measured and estimated GFRs in, 112–119
- Kidney transplantation. *See also* Kidney donors, living; Kidney transplant recipients  
  Cochrane Renal Group report, 752–756  
  for light chain deposition disease, long-term outcome of, 147–153  
  for Lowe syndrome, 538–543  
  mycophenolic acid pharmacokinetics, ferrous sulfate and, 1098–1103  
  nonimmunologic complications, 1135–1137  
  obesity and, 943–952  
  racial/ethnic disparities in, 386–387  
  referral, racial differences in, 350–357  
  status, 1116–1135
- Kidney transplant recipients  
  advanced glycation end products in, 966–975  
  children, abnormal cardiac function after, 721–726  
  with chronic allograft nephropathy, AGEs and oxidative stress in, 154–160  
  on dialysis, restless legs syndrome in, 763–771  
  early graft function, ACE inhibitor and angiotensin II blocker therapy effect on, 1065–1070  
  early renal insufficiency and late venous thromboembolism after, 120–130  
  with hepatitis C virus, ribavirin pharmacokinetics in, 140–146  
  hypertension after, 1071–1081  
  new-onset diabetes mellitus in, 953–965  
  pediatric with FSGS, differential effect of race on, 1082–1090  
  transitional cell carcinoma incidence in, 1091–1097  
  tuberculous otitis media in, 6:E25
- Kidney volume, in Australian aborigines, 254–259
- Kt/V  
  residual renal function in CAPD patients and, 1056–1064  
  survival benefit for higher dialysis doses in women, 1014–1023
- LCDD (light chain deposition disease), long-term outcome of renal transplantation in, 147–153
- Left ventricle  
  diastolic function during HD, tissue Doppler imaging of, 1040–1046  
  function, after renal transplantation, 721–726  
  hypertrophy, prognostic value of heart valve calcifications and, 479–484  
  mass, in children after renal transplantation, 721–726
- Legal issues, in withholding/withdrawal of dialysis, 181–185
- Lethargy, palliative care for, 179
- Levodopa, for restless legs syndrome in dialysis patients, 763–771
- Lifestyle changes, for chronic kidney disease with hypertension, S1:115–119
- Light chain deposition disease (LCDD), long-term outcome of renal transplantation in, 147–153
- Lipids  
  adiponectin in peritoneal dialysis patients and, 1047–1055  
  long-term aggressive lowering, effect on ischemic and atherosclerotic burden in CKD, 45–52  
  metabolism, effect of ultrapure dialysate on, 1024–1029
- Lipoprotein glomerulopathy, ApoE polymorphisms and, 223–233
- Lipoproteins, apolipoprotein B-containing, surrogate markers for, 320–329
- Liver function, HCV-infected transplant recipient survival and, 131–139

- Liver transplant recipients, with hepatitis C virus, ribavirin pharmacokinetics in, 140-146
- Losartan with benazepril, for primary glomerulonephritis, 260-268
- Low-birth weight, kidney disease during pregnancy and, 415-423
- Lowe syndrome, advanced renal insufficiency in, 538-543
- Low molecular weight heparin, adverse effects in chronic kidney disease, 531-537
- Low molecular weight proteinuria, in autosomal recessive renal proximal tubulopathy, 600-606
- Low-salt diet, in chronic kidney disease with hypertension, 782-795
- Lumbar spine, prednisolone-induced BMD loss, effects of vitamins K<sub>2</sub> and D<sub>3</sub> on, 53-60
- Lupus nephritis  
   chronic renal insufficiency, antiphospholipid antibodies and, 28-36  
   with coagulopathy, transient acute renal failure with hematuria in, 757-760  
   cyclophosphamide therapy, gonadal function preservation after, 772-781  
   diffuse proliferative, treatment of, 197-208  
   proliferative, treatment of, 383-385  
   pure membranous, prednisone and azathioprine for, 269-276
- Lyme disease, with secondary membranoproliferative glomerulonephritis, 544-551
- Lysosomal storage disease, Fabry disease with cardiac variant, renal involvement in, 164-171
- Malnutrition, reduction in chronic kidney disease, resistance training for, 607-616
- Malondialdehyde, in transplant recipients with chronic allograft nephropathy, 154-160
- Marijuana use, in hypertensive men, mild kidney function decline risk in, 629-635
- Mass screening, incidence of end-stage renal disease in Japan, 433-443
- Matrix Gla-protein, in preventing vascular calcification in chronic kidney disease, 572-579
- MCD. *See* Minimal change disease
- MDRD. *See* Modification of Diet in Renal Disease
- Medical education. *See* Nephrology core curriculum
- Medicare claims, for late venous thromboembolism after renal transplantation, 120-130
- Medicare data, pure red cell aplasia in dialysis patients, 464-470
- MEDLINE, meta-analysis of randomized controlled trials for diffuse proliferative lupus nephritis, 197-208
- Membranoproliferative glomerulonephritis (MPGN)  
   with few urinary abnormalities, 918-922  
   HCV-associated, effect of antiviral therapy on, 617-623  
   secondary to Lyme disease, 544-551
- Memory, temporal effects of dialysis in ESRD, 705-711
- Mental retardation, in Lowe syndrome, 538-543
- Messenger RNA expression profiles, of human diabetic glomeruli, 636-650
- Meta-analysis  
   effect of N-acetylcysteine for radiocontrast nephropathy prevention in CKD, 1-9  
   of randomized controlled trials for diffuse proliferative lupus nephritis, 197-208
- Metabolic alkalosis, in Gitelman's syndrome, 304-312
- Methylglyoxal, measurement in inflammatory state of CKD, 690-695
- Minimal change disease (MCD)  
   ARF in children, glomerular basal membrane changes and, 399-404  
   unexplained proteinuria in adulthood and, 933-938
- Modification of Diet in Renal Disease (MDRD), transplant recipient estimated GFR, risk for late venous thromboembolism and, 120-130
- Monoclonal gammopathy  
   kidney transplantation for, long-term outcome of, 147-153  
   of undetermined significance, case report of, 580-585
- Mortality  
   cardiac calcification in renal patients and, 234-243  
   in ESRD, protein malnutrition and hypoalbuminemia in prediction of, 61-66  
   low serum iron levels in hemodialysis patients and, 671-684  
   predialysis nephrologic care and AVF function at hemodialysis initiation and, 999-1007  
   restless legs syndrome in dialysis patients and, 763-771
- MPGN. *See* Membranoproliferative glomerulonephritis
- Muscle mass, protein requirements for hemodialysis and, 454-463
- Mutations. *See* Gene mutations
- Mycophenolate mofetil pharmacokinetics, effect of ferrous sulfate in kidney transplant patients, 1098-1103
- NADPH oxidase, Gas6/Axl signaling in inflammatory renal disease and, 286-295
- National Kidney Foundation (NKF), K/DOQI Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines
- Nausea/vomiting, palliative care for, 180
- Neointima hyperplasia, restenosis after PTA and, 74-84
- Neoplasia, after kidney transplantation, 1136-1137
- Nephrectomy, unilateral, risks of, 508-530
- Nephritis, pure membranous lupus, prednisone and azathioprine for, 269-276
- Nephrocalcinosis, in autosomal recessive renal proximal tubulopathy, 600-606
- Nephrolithiasis, risk, for living donors, 508-530
- Nephrology core curriculum, nonimmunologic complications of kidney transplantation, 1135-1137
- Nephron number, in Australian aborigines, 254-259
- Nephronophthisis, clinical and histological presentation, 358-364
- Nephropathica epidemica, urinary excretion of IL-6 correlated with proteinuria in, 809-816
- Nephrotic syndrome  
   in idiopathic focal segmental glomerulosclerosis, cyclosporine A and chlorambucil for, 10-18  
   infantile steroid-resistant, NPHS2 gene mutations and, 727-732
- Neuropathy, palliative care for, 179
- Neuropsychology, in ESRD, temporal effects of dialysis on, 705-711
- NKF-K/DOQI Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines

- Nondiabetic kidney disease  
 apolipoprotein E and, 223-233  
 apolipoprotein E polymorphisms and, 223-233  
 pharmacological therapy, S1:38
- Non-enteropathic hemolytic uremic syndrome, causes and course of, 976-982
- Nuclear magnetic resonance spectroscopy, in estimating apolipoprotein B-containing lipoproteins, 320-329
- Nutrition, prediction of vascular events and mortality in ESRD and, 61-66
- Obesity  
 evaluation of living kidney donors and, 508-530  
 kidney transplantation and, 943-952
- Occipital infarction, from intradialytic hypotension, transient visual loss and, 5:E23
- Oculocerebrorenal syndrome of Lowe, advanced renal insufficiency in, 538-543
- Oculorenal manifestations, in systemic autoimmune diseases, 209-222
- Orthostatic proteinuria, risk, for living donors, 508-530
- Osteoporosis  
 in chronic kidney disease, 566-571  
 prednisolone-induced, protective effects of vitamins K<sub>2</sub> and D<sub>3</sub>, 53-60
- Otitis media, tuberculous, in renal transplant recipient, 6:E25
- Ovarian function, preservation after cyclophosphamide therapy, 772-781
- Oxidative stress  
 in chronic allograft nephropathy, 154-160  
 chronic renal transplant dysfunction and, 966-975  
 inflammatory state of chronic renal failure and, 690-695
- Pain management  
 for intractable autosomal dominant polycystic kidney disease, 161-163  
 in renal patients, 176-178
- Palliative care, core nephropathy curriculum, 172-185
- Parathyroid hormone (PTH)  
 doxercalciferol suppression of in secondary hyperparathyroidism with CKD, 877-890  
 in renal osteodystrophy, 558-565
- Parity, kidney disease during pregnancy and, 415-423
- Patient acceptance of health care, and attitudes on racial differences in transplantation referral, 350-357
- Patient preference, empowerment for dialysis modality selection, 930-932
- PD. *See* Peritoneal dialysis
- Pediatric patients. *See* Children
- Pentosidine, in transplant recipients with chronic allograft nephropathy, 154-160
- Percutaneous transluminal angioplasty (PTA), restenotic hemodialysis vascular access, increased cell proliferation activity in, 74-84
- Peritoneal clearance limitations, in achieving phosphorus control in anuric patients, 712-720
- Peritoneal dialysis (PD). *See also* specific peritoneal dialysis modalities  
 baseline peritoneal transport status predictors and, 492-501  
 catheter removal for acute peritonitis, 103-111  
 for diabetics, peritoneal equilibrium tests for glycemic control, 927-929  
 hyperphosphatemia in Chinese patients, 712-720  
 for infectious peritonitis, transperitoneal water transport and, 485-491  
 intradermal hepatitis B vaccination in, 910-917  
 selection, effect of contraindications and patient preference on, 877-890
- Peritoneal equilibrium tests, for measuring glucose levels to determine intraperitoneal insulin for diabetic PD patients, 927-929
- Peritoneal permeability, peritoneal transport status and, 492-501
- Peritoneal transport status, baseline predictors, 492-501
- Peritonitis  
 CAPD for, transperitoneal water transport and, 485-491  
 duration, peritoneal dialysis catheter removal for, 103-111  
 peritoneal dialysis catheter removal for, 103-111  
 Permeability, transperitoneal water transport, CAPD for infectious peritonitis and, 485-491
- Persistent left superior vena cava, placement of dialysis catheter in left internal jugular vein and, 365-367
- Pharmacokinetics, of mycophenolic acid in kidney transplant recipients, ferrous sulfate and, 1098-1103
- Pharmacological therapy  
 for diabetic kidney disease, 142-158, S1:37-38  
 hypertensive chronic kidney disease, S1:36-37  
 for nondiabetic kidney disease, S1:38
- Phenotypic heterogeneity, of pediatric autosomal dominant polycystic kidney disease, 296-303
- Phosphate binders, for renal osteodystrophy, 558-565
- Phosphate removal, in hemodialysis, effect of time and exercise on, 85-89
- Phosphorus, increased levels in Chinese peritoneal dialysis patients, 712-720
- Physical function, in women with chronic kidney disease, 868-876
- Physician-patient relations, attitudes on racial differences in renal transplantation referral, 350-357
- Plasminogen activator inhibitor-1, serum AGE levels in chronic renal failure and, 690-695
- Platelet activation, in chronic kidney disease, 244-253
- Podocin gene mutations, infantile steroid-resistant nephrotic syndrome and, 727-732
- Podocytes  
 pathology, renal involvement in cardiac variant Fabry disease, 164-171  
 proliferation, cell-cycle mechanisms in focal segmental glomerulosclerosis, 19-27  
 unexplained proteinuria in adulthood and, 933-938
- Polyarteritis, microscopic, oculorenal manifestations in, 209-222
- Polyarteritis nodosa, oculorenal manifestations in, 209-222
- Polycystic kidney disease (PKD)  
 autosomal dominant. *See* Autosomal dominant polycystic kidney disease  
 enlarged liver, transcatheter arterial embolization for, 733-738

- pain-related, thoroscopic renal denervation for, 161-163
- risk
- of late venous thromboembolism after renal transplantation and, 120-130
- in living donors, 508-530
- Polymorphonuclear leukocytes (PMNLs), iron excess in hemodialysis patients, defective regulation of iron transporters and, 1030-1039
- Postinfection glomerulonephritis, Lyme disease and, 544-551
- Postoperative hospitalization, peritoneal dialysis catheter removal for peritonitis and, 103-111
- Postpartum proteinuria, prolonged, after preeclampsia, 186-191
- Potassium wasting, in Gitelman's syndrome, 304-312
- PR3-ANCA (antineutrophil cytoplasmic autoantibody specific for proteinase 3), in shunt nephritis, 5:E20
- PRCA (pure red cell aplasia), in US Medicare dialysis patients, 464-470
- Predialysis nephrologic care
- maintenance hemodialysis survival and, 999-1007
- vascular access management, 1008-1013
- Prednisolone, for diffuse proliferative lupus nephritis, 197-208
- Preeclampsia
- kidney disease during pregnancy and, 415-423
- prolonged postpartum proteinuria after, 186-191
- Pre-end-stage renal disease, initiation of dialysis in undocumented aliens, 424-432
- Pregnancy
- kidney disease as independent risk factor for adverse fetal and maternal outcomes, 415-423
- with primary hyperoxaluria, outcomes and complications of, 277-285
- restless legs syndrome in dialysis patients and, 763-771
- Prevalence
- of HCV infection in hemodialysis patients, 685-689
- of unreferral chronic kidney disease, 825-835
- Primary antiphospholipid syndrome, oculorenal manifestations in, 209-222
- Primary glomerulonephritis, low-dose dual blockade of RAS for, 260-268
- Primary hyperoxaluria, outcomes and complications of pregnancy and, 277-285
- Prognosis, prednisone and azathioprine for pure membranous lupus nephropathy and, 269-276
- Progression, unreferral chronic kidney disease, 825-835
- Proinflammatory cytokines, iron metabolism in HD patients and, 1030-1039
- Proliferative glomerulonephritis, treatment, meta-analysis of randomized controlled trials, 197-208
- Propionibacterium acne, positive titers for PR3-ANCA in shunt nephritis, 5:E20
- Protein. *See also* Proteinuria
- carbonyl
- in chronic allograft nephropathy, 154-160
- chronic renal transplant dysfunction and, 966-975
- marker reduction, ultrapure dialysate for, 1024-1029
- intake, hyperphosphatemia in Chinese peritoneal dialysis patients and, 712-720
- requirements, for hemodialysis, 454-463
- whole-body balance, in hemodialysis patients, 330-341
- Protein malnutrition, prediction of vascular events and mortality in ESRD, 61-66
- Proteinuria
- antihypertensive therapy for hypertension with chronic kidney disease and, S1:66-67
- in cardiac variant of Fabry disease, 164-171
- chronic kidney disease progression and, S1:58-59
- correlated with IL-6 excretion in hantavirus-induced nephritis, 809-816
- in hypertension with chronic kidney disease, S1:81-83
- importance in chronic kidney disease, S1:45-47
- low-dose dual blockade of RAS for, 260-268
- nephrotic-range in African-American man, 933-938
- in pediatric autosomal dominant polycystic kidney disease, 296-303
- in Still's disease with collapsing glomerulopathy, 5:E19
- Proximal kidney tubulopathy, autosomal recessive, 600-606
- Pruritus of renal disease, palliative care for, 179
- Psychedelic use, in hypertensive men, mild kidney function decline risk in, 629-635
- Psychotherapeutic programs, for weight management for obese kidney transplant recipients, 943-952
- PTA (percutaneous transluminal angioplasty), restenotic hemodialysis vascular access, increased cell proliferation activity in, 74-84
- PTH. *See* Parathyroid hormone
- Public hospitals, initiation of dialysis in undocumented aliens, 424-432
- Pulmonary embolism risk, after renal transplantation, 120-130
- Pulmonary hypertension, secondary, Bosentan for, 923-926
- Pure red cell aplasia (PRCA), in US Medicare dialysis patients, 464-470
- Puumala hantavirus-induced nephritis, urinary excretion of IL-6, correlation with proteinuria in, 809-816
- Racial differences
- in kidney transplantation, 386-387
- pediatric kidney transplant recipients with FSGS and, 1082-1090
- in predialysis vascular access management, 1008-1013
- in referral for renal transplantation, 350-357
- Radiocontrast nephropathy, prevention, *N*-acetylcysteine for, 1-9, 801-808
- Randomized controlled trials, Cochrane Renal Group report, 752-756
- RAS. *See* Renin-angiotensin system
- Recombinant human erythropoietin, PRCA-associated with in US Medicare dialysis patients, 464-470
- Reference values, for GFR in healthy potential kidney donors, 112-119
- Referrals
- for kidney transplants, racial differences in, 350-357
- late, maintenance hemodialysis survival and, 999-1007
- Registry, vascular access patterns for New Zealand hemodialysis population, 696-704
- Relative mortality risk, survival benefit for higher dialysis doses in women, 1014-1023
- Renal allograft biopsy, core curriculum in nephrology, 1116-1135



- Renal amyloidosis, with immunoglobulin  $\gamma$ -heavy chain fragment, 5:E22
- Renal artery disease  
evaluation of, S1:35-36, S1:101-106  
in hypertension with chronic kidney disease, S1:83
- Renal failure/insufficiency. *See* Acute renal failure; Chronic kidney disease
- Renal osteodystrophy  
diagnosis, assessment and treatment of bone turnover in, 558-565  
management in chronic kidney disease, 552-557
- Renal replacement therapy. *See also* specific renal replacement therapies  
with high-cutoff hemofilters, 444-453  
incidence of end-stage renal disease in Japan, 433-443
- Renal transplantation. *See* Kidney transplantation
- Renin-angiotensin system (RAS)  
blockade, in ESRD, 1113-1115  
chronic kidney disease progression and, S1:59  
low-dose dual blockade, in primary glomerulonephritis, 260-268
- Renovascular disease risk, for living donors, 508-530
- Residual renal function (RRF), in maintaining serum phosphorus levels in PD patients, 712-720
- Resistance training, to reduce malnutrition-inflammation complex syndrome in CKD, 607-616
- Restenosis, of hemodialysis vascular access after PTA, 74-84
- Restless legs syndrome  
in dialysis patients, 763-771  
with ESRD, intravenous iron dextran therapy for, 663-670  
incident hemodialysis and peritoneal dialysis, quality of life/survival and, 900-909  
palliative care for, 179
- Retinal vasculitis, in systemic autoimmune diseases, 209-222
- Reverse epidemiology, low serum iron levels in hemodialysis outcome and, 671-684
- Ribavirin  
effect on HCV-associated cryoglobulinemic MPGN, 617-623  
pharmacokinetics, in renal and liver transplant patients, 140-146
- Rituximab, for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure, 5:E24
- RRF (residual renal function), in maintaining serum phosphorus levels in PD patients, 712-720
- Sarcoidosis, oculorenal manifestations in, 209-222
- Scleritis, in systemic autoimmune diseases, 209-222
- Scleroderma, secondary pulmonary hypertension with ESRD, Bosentan for, 923-926
- Secondary hyperparathyroidism, with CKD, doxercalciferol suppression of PTH in, 877-890
- Self-management behavior education, for chronic kidney disease with hypertension, S1:107-114
- Sepsis, acute renal failure caused by, 817-824
- Sex  
high dialysis dose associated with lower mortality and, 1014-1023  
predialysis vascular access management, 1008-1013
- Sexual function, in women with chronic kidney disease, 868-876
- Shunt nephritis, with positive titers for ANCA specific for proteinase 3, 5:E20
- Sickle cell trait, risk, for living donors, 508-530
- Signal transduction, in inflammatory renal disease, 286-295
- Sjögren's syndrome, oculorenal manifestations in, 209-222
- SLE. *See* Systemic lupus erythematosus
- Smoking, evaluation of living kidney donors and, 508-530
- Sodium thiosulfate, intravenous, for calciphylaxis treatment, 1104-1108
- Solute transport, peritoneal transport status and, 492-501
- Splanchnicectomy, for pain-related intractable autosomal dominant polycystic kidney disease, 161-163
- Statins, vs. untreated dyslipidemia on serum uric acid levels in coronary heart disease, 589-599
- Still's disease, collapsing glomerulopathy in, 5:E19
- Streptococcus pneumoniae-related hemolytic uremic syndrome, causes and course of, 976-982
- Stroke, transient visual loss, occipital infarction from intradialytic hypotension and, 5:E23
- Surgical complications, of kidney transplantation, 1135
- Surgical risk evaluation, for living kidney donors, 508-530
- Survival  
of HCV-infected transplant recipients, 131-139  
restless legs symptoms in dialysis patients and, 900-909
- Sympathectomy, for pain-related intractable autosomal dominant polycystic kidney disease, 161-163
- Symptoms, of renal disease, palliative care for, 178-179
- Synthetic grafts, prevalence, in New Zealand hemodialysis population, 696-704
- Systemic inflammatory response syndrome (SIRS), acute renal failure caused by, 817-824
- Systemic lupus erythematosus (SLE). *See also* Lupus nephritis  
chronic renal insufficiency, antiphospholipid antibodies and, 28-36  
oculorenal manifestations in, 209-222  
randomized controlled trials, systematic review of, 197-208
- Takayasu's arteritis, oculorenal manifestations in, 209-222
- Technetium bone scan, of intravenous sodium thiosulfate on calciphylaxis, 1104-1108
- Testicular function, preservation after cyclophosphamide therapy, 772-781
- Thiazide-sensitive sodium chloride cotransporter, mutations, in Gitelman's syndrome, 304-312
- Thoracoscopic renal denervation, for pain-related intractable autosomal dominant polycystic kidney disease, 161-163
- Thrombosis, in lupus nephritis, antiphospholipid antibodies and, 28-36
- Time, improvement of phosphate removal in hemodialysis and, 85-89
- Time series, marked reduction of HCV infection prevalence in hemodialysis patients, 685-689
- Tissue Doppler imaging, assessment of left ventricular diastolic function during hemodialysis, 1040-1046
- Total-body nitrogen, prediction of vascular events and mortality in ESRD, 61-66



- Transarterial embolization, for renal arteriovenous malformation, delayed complications from, 1109-1112
- Transcatheter arterial embolization, for enlarged polycystic liver, 733-738
- Transferrin receptor, upregulation, iron levels in PMNLs of maintenance hemodialysis patients and, 1030-1039
- Transferrin saturation ratio, outcome prediction for hemodialysis patients and, 671-684
- Transitional cell carcinoma incidence, after kidney transplantation in Taiwan, 1091-1097
- Transjugular renal biopsy, for high-risk patients, 651-662
- Transplant dysfunction, chronic, advanced glycation end products and, 966-975
- Triglycerides
- adiponectin in peritoneal dialysis patients and, 1047-1055
  - effect of ultrapure dialysate on, 1024-1029
- Troponin T levels, clinical significance in chronic kidney disease, 846-853
- Tuberculous otitis media, in renal transplant recipient, 6:E25
- Tubulointerstitial nephritis, oculorenal manifestations in, 209-222
- Tumor necrosis factor- $\alpha$
- inflammatory state in chronic renal failure and, 690-695
  - serum AGE levels in chronic renal failure and, 690-695
  - urinary excretion, in hantavirus-induced nephritis, 809-816
- Ultrafiltration, for infectious peritonitis, transperitoneal water transport and, 485-491
- Unilateral nephrectomy, impact on children, 508-530
- United States Renal Data System (USRDS), posttransplant CKD, late venous thromboembolism and, 120-130
- Unreferred chronic kidney disease, longitudinal study of, 825-835
- Urea kinetics, early changes in daily hemodialysis, 90-102
- Urea reduction ratio (URR), survival benefit for higher dialysis doses in women, 1014-1023
- Uremia
- adiponectin in peritoneal dialysis patients and, 1047-1055
  - heart valve calcifications in hemodialysis patients and, 479-484
  - restless legs syndrome in dialysis patients and, 763-771
- Uric acid, serum, effects of statins versus untreated dyslipidemia in coronary heart disease, 589-599
- Urinalysis
- incidence of end-stage renal disease in Japan, 433-443
  - membranoproliferative glomerulonephritis with few urinary abnormalities, 918-922
- Urolithiasis, in pregnancy, outcomes and complications of, 277-285
- URR (urea reduction ratio), survival benefit for higher dialysis doses in women, 1014-1023
- USRDS (United States Renal Data System), posttransplant CKD, late venous thromboembolism and, 120-130
- Uveitis syndrome
- oculorenal manifestations in, 209-222
  - in systemic autoimmune diseases, 209-222
- Valine turnover, in hemodialysis patients, 330-341
- Valsartan, effect on residual renal function in CAPD patients, 1056-1064
- Vascular access. *See also* specific vascular access methods
- maintenance hemodialysis survival and, 999-1007
  - practice patterns in New Zealand hemodialysis population, 696-704
  - predialysis management of, 1008-1013
- Vascular adhesion molecule-1
- inflammatory state in chronic renal failure and, 690-695
  - serum AGE levels in chronic renal failure and, 690-695
- Vascular calcification, in chronic kidney disease, 572-579
- Vascular disease, prediction in ESRD, protein malnutrition and hypoalbuminemia in, 61-66
- Vascular endothelial growth factor (VEGF), inflammatory state in chronic renal failure and, 690-695
- Vasculitis, in systemic autoimmune diseases, 209-222
- VEGF (vascular endothelial growth factor), serum AGE levels in chronic renal failure and, 690-695
- Visual loss, occipital infarction from intradialytic hypotension and, 5:E23
- Vitamin D and vitamin D analogs
- doxercalciferol suppression of PTH levels in secondary hyperparathyroidism with CKD, 877-890
  - effects on prednisolone-induced BMD loss in lumbar spine, 53-60
  - for renal osteodystrophy, 558-565
- Vitamin K, prednisolone-induced BMD loss in lumbar spine and, 53-60
- Warfarin coagulopathy, in lupus nephritis with transient acute renal failure and hematuria, 757-760
- Wegner's granulomatosis, oculorenal manifestations in, 209-222
- Wilms' tumor protein-1, in focal segmental glomerulosclerosis, podocyte proliferation and, 19-27
- Withholding/withdrawal of dialysis, clinical, ethical and legal issues in, 181-185
- Women
- with chronic kidney disease, physical and sexual function in, 868-876
  - with heart disease, creatinine levels and cardiovascular events in, 37-44
  - outcomes and complications of pregnancy with primary hyperoxaluria, 277-285